<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006532</article-id><article-id pub-id-type="pmc">PMC11859826</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020165</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2731-1071</contrib-id><name><surname>Alyami</surname><given-names>Mohammad H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceutics-17-00165" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3513-4976</contrib-id><name><surname>Alyami</surname><given-names>Hamad S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceutics-17-00165" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00165" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-8473-6089</contrib-id><name><surname>Abdo</surname><given-names>Asmaa M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-pharmaceutics-17-00165" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00165" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8327-7192</contrib-id><name><surname>A. Sabry</surname><given-names>Shereen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00165" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-3083-2179</contrib-id><name><surname>Mansour</surname><given-names>Shimaa M. G.</given-names></name><xref rid="af3-pharmaceutics-17-00165" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9148-3276</contrib-id><name><surname>El-Nahas</surname><given-names>Hanan M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00165" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9397-2129</contrib-id><name><surname>Ayoub</surname><given-names>Margrit M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceutics-17-00165" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Conway</surname><given-names>Barbara R.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00165"><label>1</label>Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 66462, Saudi Arabia</aff><aff id="af2-pharmaceutics-17-00165"><label>2</label>Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt</aff><aff id="af3-pharmaceutics-17-00165"><label>3</label>Department of Virology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt</aff><author-notes><corresp id="c1-pharmaceutics-17-00165"><label>*</label>Correspondence: <email>hsalmukalas@nu.edu.sa</email> (H.S.A.); <email>phasmaa98@gmail.com</email> (A.M.A.)</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>165</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Infectious bronchitis virus (IBV) causes a significant illness in birds, making it a leading source of financial loss in the poultry business. The objective of this study was to assess the effectiveness of proliposomes (PLs) containing ivermectin (IVM) against IBV using embryonated chicken eggs (ECEs). <bold>Methods</bold>: A three-factor, two-level (2<sup>3</sup>) full factorial design was employed; carrier/lipid phase ratio (A), stearyl glycyrrhetinate amount (B), and phospholipid type (C) were studied as independent variables, while product yield (PY), entrapment efficiency (EE), particle size (PS), polydispersity index (PDI), zeta potential (ZP), and cumulative percentage of drug released after 6 h (Q6h) were characterized. The selected formulations (PL2 and PL6) were subjected to further characterizations, including IVM toxicity and anti-viral activity. <bold>Results</bold>: The PY% ranged from 88.6 &#x000b1; 2.19% to 98.8 &#x000b1; 0.45%, EE% was from 71.8 &#x000b1; 2.01% to 96.1 &#x000b1; 0.51%, PS was from 330.1 &#x000b1; 55.65 nm to 1801.6 &#x000b1; 45.61 nm, PDI was from 0.205 &#x000b1; 0.06 to 0.603 &#x000b1; 0.03, ZP was from &#x02212;18.2 &#x000b1; 0.60 mV to &#x02212;50.1 &#x000b1; 1.80 mV, and Q6h was from 80.95 &#x000b1; 1.36% to 88.79 &#x000b1; 2.03%. IVM-loaded PLs had lower toxicity in ECEs than pure IVM; the mortality rate was substantially reduced in IBV-infected ECEs injected with PL2 rather than pure IVM. As further evidence of IVM&#x02019;s anti-viral action against IBV, quantitative real-time polymerase chain reaction (qRT-PCR) revealed that the PL2-treated group exhibited further reduction in IBV&#x02019;s copies in comparison with the pure IVM-treated group. <bold>Conclusions</bold>: PLs loaded with IVM are an innovative and potentially effective way to inhibit IBV.</p></abstract><kwd-group><kwd>infectious bronchitis virus</kwd><kwd>proliposomes</kwd><kwd>ivermectin</kwd><kwd>mannitol</kwd><kwd>stearyl glycyrrhetinate</kwd></kwd-group><funding-group><award-group><funding-source>the Deanship of Graduate Studies and Scientific Research at Najran University under the Easy Funding Program</funding-source><award-id>NU/EFP/SERC/13/167</award-id></award-group><funding-statement>This research was funded by the Deanship of Graduate Studies and Scientific Research at Najran University under the Easy Funding Program grant code NU/EFP/SERC/13/167.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00165"><title>1. Introduction</title><p>The poultry industry is being threatened financially by avian infectious bronchitis virus (IBV), which is the coronavirus of the chicken (<italic toggle="yes">Gallus gallus</italic>), and causes an acute, highly contagious upper respiratory tract disease. IBV affects the performance of both meat-type and egg-laying birds and chickens of all ages [<xref rid="B1-pharmaceutics-17-00165" ref-type="bibr">1</xref>]. No risks to human health are suspected or have been demonstrated to arise from IBV [<xref rid="B2-pharmaceutics-17-00165" ref-type="bibr">2</xref>]. IBV and other avian coronaviruses of turkeys and pheasants are classified as <italic toggle="yes">Gammacoronaviruses</italic>, while mammalian coronaviruses comprise <italic toggle="yes">Alpha</italic> and <italic toggle="yes">Betacoronaviruses</italic> [<xref rid="B3-pharmaceutics-17-00165" ref-type="bibr">3</xref>].</p><p>The COVID-19 pandemic spread across the world at an alarming rate in the first quarter of 2020. The research for treating the condition sparked intense attention in the medical world. There have been many attempts at repurposing existing and approved drugs for the treatment of COVID-19. Anti-virals, anti-parasitics, and anti-inflammatory drugs were among those that attracted a lot of media attention. Remdesivir, baricitinib, choloroquine/hydroxychloroquine, famotidine, ivermectin, and other drugs were tested [<xref rid="B4-pharmaceutics-17-00165" ref-type="bibr">4</xref>].</p><p>Ivermectin (IVM) is widely used in both animals and humans as a Food and Drug Administration (FDA)-approved parasiticide [<xref rid="B5-pharmaceutics-17-00165" ref-type="bibr">5</xref>]. It is the common name of 22,23-dihydroavermectins B1 and it is a semi-synthetic derivative of avermectins that is produced from naturally occurring fermentation products [<xref rid="B6-pharmaceutics-17-00165" ref-type="bibr">6</xref>]. Ivermectin is a broad spectrum anti-parasitic agent belonging to the macrocyclic lactone group; it treats several neglected tropical diseases, including onchocerciasis, helminthiases, scabies, and other parasitic infections [<xref rid="B7-pharmaceutics-17-00165" ref-type="bibr">7</xref>]. It is widely used in low- and middle-income countries (LMICs) to treat worm infections [<xref rid="B8-pharmaceutics-17-00165" ref-type="bibr">8</xref>]. IVM is a non-hygroscopic crystalline powder that belongs to class II/IV in the biopharmaceutics classification system (BCS) [<xref rid="B9-pharmaceutics-17-00165" ref-type="bibr">9</xref>]. It has limited aqueous solubility; consequently, it has low oral bioavailability [<xref rid="B10-pharmaceutics-17-00165" ref-type="bibr">10</xref>].</p><p>There are several studies focusing on the anti-viral activity of IVM with demonstrated pre-clinical activity against chikungunya virus [<xref rid="B11-pharmaceutics-17-00165" ref-type="bibr">11</xref>], pseudorabies virus [<xref rid="B12-pharmaceutics-17-00165" ref-type="bibr">12</xref>], West Nile virus [<xref rid="B13-pharmaceutics-17-00165" ref-type="bibr">13</xref>], and more lately, in vitro activity against SARS-CoV-2, the causative agent of COVID-19 [<xref rid="B14-pharmaceutics-17-00165" ref-type="bibr">14</xref>]. Until now, the FDA has not approved or authorized IVM for use in preventing or treating COVID-19 in humans or animals; the evidence on IVM for the prevention of severe acute respiratory syndrome (SARS)-CoV-2 infection and COVID-19 treatment is still conflicting [<xref rid="B5-pharmaceutics-17-00165" ref-type="bibr">5</xref>]. The National Institutes of Health in the United States recently stated that &#x0201c;There are insufficient data to recommend either for or against the use of IVM for the treatment of COVID-19&#x0201d;; the world health organization (WHO) recommends against its use outside of clinical trials [<xref rid="B15-pharmaceutics-17-00165" ref-type="bibr">15</xref>].</p><p>Although there is demonstrated efficacy of IVM, its activity was limited because of some critical issues related to the currently available dosage forms, i.e., tablets, capsules, and suspensions [<xref rid="B16-pharmaceutics-17-00165" ref-type="bibr">16</xref>]. Therefore, several studies were conducted to formulate IVM in micro- and nanoparticles including polymer nanocapsules [<xref rid="B17-pharmaceutics-17-00165" ref-type="bibr">17</xref>], chitosan&#x02013;alginate nanoparticles [<xref rid="B18-pharmaceutics-17-00165" ref-type="bibr">18</xref>], nanolipid carriers [<xref rid="B19-pharmaceutics-17-00165" ref-type="bibr">19</xref>], and self-implanted tiny needles [<xref rid="B20-pharmaceutics-17-00165" ref-type="bibr">20</xref>].</p><p>There are many studies on the role of licorice extract in managing COVID-19 [<xref rid="B21-pharmaceutics-17-00165" ref-type="bibr">21</xref>]. The main triterpenoid active constituents of licorice extract are glycyrrhizin (glycyrrhizic acid), glycyrrhetinic acid, and its derivatives [<xref rid="B22-pharmaceutics-17-00165" ref-type="bibr">22</xref>]. It was shown that glycyrrhizic acid could inhibit coronavirus replication in vitro [<xref rid="B23-pharmaceutics-17-00165" ref-type="bibr">23</xref>]. It was reported that using a small dose of glycyrrhizin, about 10&#x02013;50 mg, in licorice extract as a daily prophylactic dose and a large dose of about 50&#x02013;100 mg three times a day can prevent the progression of the disease during its initial phase [<xref rid="B22-pharmaceutics-17-00165" ref-type="bibr">22</xref>]. Glycyrrhizin is a conjugate of glycyrrhetinic acid and two molecules of glucuronic acid. Glycyrrhetinic acid is a pentacyclic lactone with a structure similar to that of cortisone, so it is responsible for the anti-inflammatory effect of licorice extract [<xref rid="B24-pharmaceutics-17-00165" ref-type="bibr">24</xref>]. Stearyl glycyrrhetinate (SG) is the salt and ester of glycyrrhetinic acid.</p><p>Liposomes are a lipid-based drug delivery system; they were found to be the most promising drug delivery system to encapsulate the lipophilic drugs [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>]. Phospholipid degradation by hydrolysis or oxidation in aqueous dispersion followed by aggregation, sedimentation, and leakage of the encapsulated drug is the main drawback of liposomes [<xref rid="B26-pharmaceutics-17-00165" ref-type="bibr">26</xref>]. Proliposomes (PLs) are a novel type of carrier-mediated drug delivery system; they are a promising strategy to improve liposomes&#x02019; physicochemical properties and stability [<xref rid="B27-pharmaceutics-17-00165" ref-type="bibr">27</xref>]. Proliposomes are dry, free-flowing particles that immediately form liposomal dispersion of multilamellar vesicles upon contact with water or biological fluid; the resulting liposomal vesicles are similar to conventional liposomes and more uniform in size [<xref rid="B28-pharmaceutics-17-00165" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-17-00165" ref-type="bibr">29</xref>]. The superiority of PLs over liposomes for drug delivery is due to their stability [<xref rid="B29-pharmaceutics-17-00165" ref-type="bibr">29</xref>]. Moreover, the solubility and bioavailability problems of many drugs can be overcome by developing PLs formulations [<xref rid="B30-pharmaceutics-17-00165" ref-type="bibr">30</xref>].</p><p>No research has been published on enhancing the action of IVM through its formulation in a PLs system. This study set out to formulate, optimize IVM-loaded PLs and SG-modified IVM-loaded PLs, and investigate their anti-viral efficacy against avian IBV using ECEs. For this purpose, different variables influencing vesicles&#x02019; characteristics were studied employing 2<sup>3</sup> full factorial design using Design Expert<sup>&#x000ae;</sup> software, version 11 to identify the optimized formulation. The selected formulations were subjected to further characterizations, such as scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and stability studies; additionally, investigations into IVM toxicity and anti-viral activity against IBV-infected ECEs were performed.</p></sec><sec id="sec2-pharmaceutics-17-00165"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00165"><title>2.1. Materials</title><p>Ivermectin was kindly supplied by Delta Pharma Co., Cairo, Egypt. Soybean phosphatidylcholine (SPC; Lipoid S-100) was kindly gifted by Lipoid, Steinhausen, Switzerland. Dipalmitoyl phosphatidylcholine (DPPC) was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Stearyl glycyrrhetinate was supplied by Tokyo Chemical Industry Co., Ltd., Tokyo, Japan. Cholesterol was purchased from BDH Chemicals Ltd., London, UK. Ethanol, potassium di-hydrogen orthophosphate, di-sodium hydrogen orthophosphate, and sodium lauryl sulfate (SLS) were purchased from El-Naser pharmaceuticals Chemicals Co. (Cairo, Egypt). All other chemicals were of analytical grade and used as received.</p></sec><sec id="sec2dot2-pharmaceutics-17-00165"><title>2.2. Methods</title><sec id="sec2dot2dot1-pharmaceutics-17-00165"><title>2.2.1. Experimental Design</title><p>The IVM-loaded PLs were prepared following the three-factor, two-level (2<sup>3</sup>) full factorial experimental design using Design-Expert<sup>&#x000ae;</sup> software (version 11, Stat-Ease Inc., Minneapolis, MN, USA). The experimental design is a scientific technique used to study the effect of the independent variables (factors) on the measured dependent variables (responses). Carrier/lipid phase ratio (A), stearyl glycyrrhetinate amount (B), and phospholipid type (C) were selected as independent variables. In addition, the measured responses were set, including PY% (Y<sub>1</sub>), EE% (Y<sub>2</sub>), PS (Y<sub>3</sub>), PDI (Y<sub>4</sub>), ZP (Y<sub>5</sub>), and Q6h (Y<sub>6</sub>). The goal was to optimize a PLs formulation loaded with IVM to have favorable characteristics regarding the goal criteria that could achieve the study aim. The two different levels of the independent factors and the goal criteria for the measured responses are shown in <xref rid="pharmaceutics-17-00165-t001" ref-type="table">Table 1</xref>. An analysis of variance (ANOVA) test was adopted, measuring several parameters such as the multiple correlation coefficient (R<sup>2</sup>), adjusted R<sup>2</sup>, predicted R<sup>2</sup>, and adequate precision, to analyze the obtained data for assessing the model significance and to prove the statistical analysis of the data. Moreover, the graphs of 3-D response surface plots and one-factor plots were studied to assess the significant relationship between the studied factors and the measured responses, and the linearity plots of the observed versus predicted values were studied to ensure the validity of the chosen model for different responses.</p></sec><sec id="sec2dot2dot2-pharmaceutics-17-00165"><title>2.2.2. Preparation of IVM-Loaded PLs Formulations</title><p>The IVM-loaded PLs formulations were prepared using various ratios of SPC, DPPC, cholesterol, mannitol, and SG (<xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>). The lipid phase (300 mg) consisted of 210 mg SPC or DPPC and 90 mg of cholesterol. The PLs were prepared with a range of carrier/lipid phase ratio (6:1 and 9:1 <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) via the slurry method, as reported previously by Khan et al. [<xref rid="B31-pharmaceutics-17-00165" ref-type="bibr">31</xref>] with minor modifications. This was achieved by coating 300 mg of lipid phase onto 1800 mg or 2700 mg of mannitol. Firstly, the carbohydrate carrier (mannitol) was sieved with 100 mesh and placed in a 50 mL pear-shaped flask, which was held at 70 &#x000b0;C, and the flask was rotated at 90 rpm using the rotary evaporator (Basis Hei-VAP HL, Heidolph Instruments GmbH &#x00026; Co. KG, Schwabach, Germany). The rotating flask was kept in a water bath (Heizbad Hei-VAP, Heidolph Instruments GmbH &#x00026; Co. KG, Schwabach, Germany) and mannitol was dried under vacuum for 30 min. Briefly, the required amounts of IVM (6 mg), phospholipid, cholesterol, and SG were weighed and dissolved in ethanol (333 mg/mL). The resultant mixture was transferred to the pear-shaped flask after mannitol drying. A rotary evaporator was used to evaporate the ethanol from the slurry, using a vacuum pump (Buchi Vac V-501, Buchi AG, Flawil, Switzerland), and to set up the water bath of the evaporator at 45 &#x000b0;C and the rotation speed at 250 rpm for 2 h. The PLs granules were harvested and sieved with 100 mesh, then collected and stored at &#x02212;18 &#x000b0;C for conducting the subsequent studies.</p></sec><sec id="sec2dot2dot3-pharmaceutics-17-00165"><title>2.2.3. Characterization of IVM-Loaded PLs Formulations</title><sec><title>Estimation of Product Yield (PY%)</title><p>After preparation of the IVM-loaded PLs, it was collected and weighed accurately. The product yield was determined according to the following equation [<xref rid="B28-pharmaceutics-17-00165" ref-type="bibr">28</xref>]:<disp-formula>PY (%) = (W&#x000b0;/WT) &#x000d7; 100</disp-formula>
where W&#x000b0; = total weight of PLs, WT = sum of initial weight of mannitol, phospholipid, cholesterol, and drug(s) employed.</p></sec><sec><title>Estimation of Entrapment Efficiency (EE%)</title><p>After hydrating 100 mg of PLs with 10 mL of distilled water (DW) [<xref rid="B8-pharmaceutics-17-00165" ref-type="bibr">8</xref>], vortex-mixing was conducted for two minutes to ensure complete dissolution of the carrier particles and hydration/dispersion of the lipid [<xref rid="B31-pharmaceutics-17-00165" ref-type="bibr">31</xref>]. The EE of IVM in the reconstituted liposomes was assessed via centrifugation of the liposomal suspension for 60 min at 4 &#x000b0;C and 13,000 rpm. In order to remove the unentrapped (free) drug, the clear supernatant was siphoned off and the pellets were resuspended and centrifugated again to ensure that the free drug was completely removed. At &#x003bb;max (246 nm), the free drug concentration was determined spectrophotometrically [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>].</p><p>The EE% was calculated according to the following equation [<xref rid="B32-pharmaceutics-17-00165" ref-type="bibr">32</xref>]:<disp-formula>EE (%) = [(total drug loading &#x02212; unentrapped drug)/total drug loading] &#x000d7; 100</disp-formula></p></sec><sec><title>Estimation of Particle Size (PS) and Polydispersity Index (PDI)</title><p>The PS and PDI of liposomes generated upon hydration of the prepared PLs were analyzed by laser diffraction according to the method reported by Byeon et al. [<xref rid="B33-pharmaceutics-17-00165" ref-type="bibr">33</xref>]. Proliposomes (20 mg) were mixed with 10 mL of DW and dispersed well to obtain homogenous particles; then, the PS was measured by a computerized Malvern Zetasizer Nano-ZS90 (Malvern Instruments Ltd., Malvern, UK). The measurements were carried out in triplicate after equilibration at 25 &#x000b0;C for 2 min.</p></sec><sec><title>Zeta Potential Measurement (ZP)</title><p>The ZP of vesicles was determined using a computerized Malvern Zetasizer Nano-ZS90 (Malvern Instruments Ltd., Malvern, UK) by selecting the instrument&#x02019;s relevant software option. Liposomes generated upon hydration of the prepared PLs were loaded into the Malvern&#x02019;s zeta potential cells. ZP was determined after setting the temperature at 25 &#x000b0;C and allowing 2 min for sample equilibration, in order to obtain consistent ZP.</p></sec><sec><title>Cumulative Percentage of Drug Released After 6 h (Q6h)</title><p>The release of IVM from the prepared formulations was performed using the dialysis bag method according to the method conducted by Karn et al. [<xref rid="B34-pharmaceutics-17-00165" ref-type="bibr">34</xref>] with minor modifications. The PLs formulations equivalent to 4 mg of drug were sealed in dialysis bags by tightening the two ends of the tube with a thin thread. Then, each dialysis bag containing a sample was immersed in a glass bottle containing 20 mL of phosphate buffer pH 6.8 containing 0.5% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) of sodium lauryl sulfate. The bottles were shaken at 50 rpm and 37 &#x000b1; 0.5 &#x000b0;C. Aliquots of 1 mL were taken from each bottle at different time intervals (0.5, 1, 1.5, 2, 3, 4, 5, and 6 h). Samples were analyzed for the drug content at 246 nm using phosphate buffer pH 6.8 containing 0.5% SLS as a blank. The dissolution medium was replaced with fresh medium to maintain the sink condition. The process of buffer preparation, dissolution studies, and analytical procedures were all conducted at 37 &#x000b1; 0.5 &#x000b0;C. Each sample was run in triplicate. Then, the standard error of mean values was calculated.</p></sec><sec><title>Kinetic Study of Drug Release</title><p>To determine the in vitro release mechanism of all PLs formulations, the release data were subjected to the following models: zero order model (Q<sub>t</sub> = K<sub>o</sub>&#x000b7;t), first order model (log Q<sub>t</sub> = log Q<sub>o</sub> &#x02212; K&#x000b7;t/2.303), Higuchi release model (Q<sub>t</sub> = K<sub>H</sub>&#x000b7;t0.5), Korsmeyer&#x02013;Peppas model (Q<sub>t</sub>/Q<sub>&#x0221e;</sub> = K<sub>kp</sub>&#x000b7;tn), and Hixson&#x02013;Crowell model (Qo<sup>1/3</sup> &#x02212; Qt<sup>1/3</sup> = K<sub>s</sub>&#x000b7;t) where Q<sub>t</sub> is the amount of drug released at time (t), Q<sub>o</sub> is the initial drug amount, Q<sub>&#x0221e;</sub> is the amount of drug released at time infinity (&#x0221e;), K<sub>o</sub>, K, k<sub>H</sub>, K<sub>kp</sub>, K<sub>s</sub> are the release rate constants of the previous models, respectively, and n is the release exponent. The model of highest correlation coefficient (R<sup>2</sup>) was considered as the best fit model. Furthermore, the mechanism of drug release was confirmed by the n value of the Korsmeyer&#x02013;Peppas model [<xref rid="B35-pharmaceutics-17-00165" ref-type="bibr">35</xref>].</p></sec></sec><sec id="sec2dot2dot4-pharmaceutics-17-00165"><title>2.2.4. Optimization Technique</title><p>The optimization process was performed after the statistical analysis. The optimized formulation was selected by the design software depending on the goal criteria, which is the minimization of PS and PDI and maximization of PY%, EE%, ZP (as an absolute value), and Q6h, as investigated in <xref rid="pharmaceutics-17-00165-t001" ref-type="table">Table 1</xref>. The validity of the models was determined according to the optimized formulation&#x02019;s desirability value and the closeness of experimental values to the predicted ones by the design [<xref rid="B36-pharmaceutics-17-00165" ref-type="bibr">36</xref>]. The optimized formulation was evaluated by further characterization tests.</p></sec><sec id="sec2dot2dot5-pharmaceutics-17-00165"><title>2.2.5. Characterization of the Selected Formulations</title><sec><title>Scanning Electron Microscopy (SEM)</title><p>The surface morphology of the selected formulations (PL2 and PL6) and pure mannitol was examined using SEM. The samples were sprinkled onto a cupper stub and coated with gold by a sputter coater under a high vacuum. The particles were observed and images were captured under SEM (JEOL JSM 6510 Iv; JEOL, Tokyo, Japan) at an accelerating voltage of 20&#x02013;30 KV.</p></sec><sec><title>Differential Scanning Calorimetry (DSC)</title><p>Differential scanning calorimetric analysis was conducted to investigate the solid-state properties of the selected formulations. The DSC thermograms of pure IVM, SG, SPC, cholesterol, mannitol, the selected formulations (PL2 and PL6), and the blank formulation were carried out using a DSC instrument (DSC 60, Shimadzu Co., Kyoto, Japan). About 2 mg of each sample was placed in an aluminum pan and sealed. Each sample was heated to 200 &#x000b0;C at a ramping speed of 10 &#x000b0;C/min under a nitrogen purge (20 mL/min).</p></sec><sec><title>Fourier Transform Infrared Spectroscopy (FTIR)</title><p>In order to determine drug&#x02013;excipient compatibility, comparisons were made between the FTIR spectra of pure IVM, SG, SPC, cholesterol, mannitol, the selected formulations (PL2 and PL6), and the blank formulation by using a Perkin-Elmer FTIR spectrophotometer (series 1600, Perkin-Elmer Corporation, Waltham, MA, USA) under vacuum from 4000 to 400 cm<sup>&#x02212;1</sup> with a resolution of 4 cm<sup>&#x02212;1</sup> through the potassium bromide disk method.</p></sec><sec><title>Stability Studies</title><p>Stability studies were performed by analyzing the physical appearance, EE, PS, and ZP of selected formulations (PL2 and PL6) upon storage at room temperature 25 &#x000b1; 1 &#x000b0;C and refrigerated conditions 4 &#x000b1; 1 &#x000b0;C for 3 months. Samples were examined at 1, 2, and 3 months and the results were compared with the initial measurements of the freshly prepared formulation [<xref rid="B37-pharmaceutics-17-00165" ref-type="bibr">37</xref>]. Statistical analysis was performed by applying the two-way ANOVA test using GraphPad Prism, version 8.</p></sec></sec><sec id="sec2dot2dot6-pharmaceutics-17-00165"><title>2.2.6. Investigation of the Anti-Viral Activity Against IBV</title><sec><title>Ethical Statement</title><p>An embryonated chicken eggs (ECEs) model was used to investigate the activity of pure IVM and selected formulations (PL2 and PL6) against IBV (IB MA5). The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) guidelines of the Faculty of Pharmacy, Zagazig University (Approval number: ZU-IACUC/3/F/438/2022).</p></sec><sec><title>Virus</title><p>The Massachusetts type of avian infectious bronchitis live vaccine virus (MSD) was used. The lyophilized vaccine was first reconstituted with 10 mL sterile phosphate-buffered saline (PBS) and then further diluted in PBS to contain 103 EID50 per 100 &#x000b5;L (median egg infective dose 50 per 100 &#x000b5;L).</p></sec><sec><title>Toxicity Study</title><p>Nine-day-old chicken embryos (<italic toggle="yes">Gallus gallus domesticus</italic>) were supplied by a commercial-certified hatchery. Prior to incubation, the eggs were cleaned with 70% ethanol-wetted cotton pieces. Eggs were then candled in a dark room to mark the boundary of the air sac and the head spot using a lead pencil. The maximum non-toxic concentration (MNTC) was determined according to the method previously described by Ghoke et al. [<xref rid="B38-pharmaceutics-17-00165" ref-type="bibr">38</xref>] with minor modifications. To determine the MNTC of pure IVM, PL2, and PL6, ten-day-old ECEs were divided into four groups (group I, inoculated with pure IVM; group II, inoculated with PL2; group III, inoculated with PL6; and group IV, negative control group).</p><p>Serial two-fold dilution of pure IVM, PL2, and PL6 was prepared to achieve 400 &#x000b5;M, 200 &#x000b5;M, 100 &#x000b5;M, 50 &#x000b5;M, 25 &#x000b5;M, 12.5 &#x000b5;M, and 6.25 &#x000b5;M of IVM. Precisely 0.1 mL of two-fold dilution of pure IVM, PL2, and PL6 was inoculated into the allantoic cavity of the ECEs (three eggs for each dilution). The 4th group contained 6 eggs and was kept as a negative control (not receiving any treatment). All the ECEs were placed in an incubator already adjusted at 37 &#x000b1; 1 &#x000b0;C with a relative humidity of 60&#x02013;70%.</p><p>All the ECEs were candled after 24 h, and any dead embryos were removed. The candling of eggs was conducted twice daily till hatching to check the viability of embryos for different concentrations of pure IVM, PL2, and PL6; the dead embryos were placed in the refrigerator. After 7 days of incubation, two eggs from each dilution of pure IVM, PL2, and PL6 were randomly selected and placed in the refrigerator for chilling at 4 &#x000b1; 1 &#x000b0;C overnight. Each egg was examined for any sign of lesions.</p></sec><sec><title>Assay of Anti-Viral Activity</title><p>Investigation of the anti-viral activity of pure IVM, PL2, and PL6 against IBV using ECEs was performed according to the method previously described by Azeem et al. [<xref rid="B39-pharmaceutics-17-00165" ref-type="bibr">39</xref>] with minor modifications. ECEs were prepared as described in the previous section and then divided into five groups (group I, IBV infected and treated with pure IVM; group II, IBV infected and treated with PL2; group III, IBV infected and treated PL6; group IV, IBV infected and not-treated; group V, not-infected and not-treated).</p><p>Viral inoculums were injected through the allantoic route in ECEs of group 1 up to 3 and incubated at 37 &#x000b1; 1 &#x000b0;C. A serial two-fold dilution of pure IVM, PL2, and PL6 was prepared to achieve 200 &#x000b5;M, 100 &#x000b5;M, and 50 &#x000b5;M of IVM. Precisely 0.1 mL of the two-fold dilution of pure IVM, PL2, and PL6 was inoculated into the allantoic cavity of the IBV-infected ECEs (three eggs for each dilution). The 4th group contained 6 eggs and was kept as a positive control (infected, non-treated; injected with 0.1 mL of viral suspension under similar experimental conditions), while the 5th group contained 6 eggs and was kept as a negative control (non-infected, non-treated).</p><p>The inoculated ECEs were placed in an incubator already adjusted at 37 &#x000b1; 1 &#x000b0;C with relative humidity of 60&#x02013;70% for the period of 5 days. All the ECEs were candled after 24 h, and any dead embryos were removed. The candling of eggs was conducted twice daily to check the viability of embryos, and the dead embryos were placed in the refrigerator. Then, after 5 days of incubation, the live eggs were placed in the refrigerator for chilling at 4 &#x000b1; 1 &#x000b0;C overnight to examine any viral lesion in the embryos. This assay was performed in two separate trials and the results were statistically analyzed using GraphPad Prism version 8. Statistical significance was assessed by two-way analysis of variance (ANOVA) with Tukey post-hoc test. Values are expressed as mean &#x000b1; standard error of mean.</p></sec><sec><title>RNA Extraction, Reverse Transcription, and qRT-PCR</title><p>The allantoic fluids were collected 72 h post-inoculation and submitted for quantitative real-time polymerase chain reaction (qRT-PCR) analysis to determine the viral load. Total RNA rapid extraction kits (Qiagen, QIAamp<sup>&#x000ae;</sup> MinElute<sup>&#x000ae;</sup> Virus Kits, Hilden, Germany, Cat. # 57704) were used for total RNA extraction from 200 &#x000b5;L of allantoic fluids (according to manufacturer&#x02019;s instructions).</p><p>One-step RT-PCR was conducted according to the manufacturer&#x02019;s protocol (Reliance One-Step Multiplex Supermax, Bio-Rad, USA, Cat. # 12010176) using a qRT-PCR thermal-cycler system (CFX Opus 96, New York, NY, USA). A forward primer (5&#x02032;-GCT TTT GAG CCT AGC GTT-3&#x02032;), a reverse primer (5&#x02032;-GCC ATG TTG TCA CTG TCT ATT G-3&#x02032;), and a Taqman<sup>&#x000ae;</sup> labeled probe (5&#x02032;-CAC CAC CAG AAC CTG TCA CCT C-BHQ1-3&#x02032;) were used [<xref rid="B40-pharmaceutics-17-00165" ref-type="bibr">40</xref>]. Firstly, cDNA was formed using reverse transcriptase at 50 &#x000b0;C for 15 min followed by denaturation at 95 &#x000b0;C for 10 min. Then, 40 cycles of qRT-PCR were conducted by repeating the following steps for each cycle: denaturation at 95 &#x000b0;C for 15 s, annealing at 57 &#x000b0;C for 20 s, and extension at 72 &#x000b0;C for 30 s. For each reaction, the cycle threshold (CT) number was determined [<xref rid="B40-pharmaceutics-17-00165" ref-type="bibr">40</xref>] and used to calculate amount of cDNA in each sample.</p></sec></sec></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00165"><title>3. Results and Discussion</title><sec id="sec3dot1-pharmaceutics-17-00165"><title>3.1. Preliminary Studies for Preparation of IVM-Loaded PLs</title><p>Ivermectin-loaded PLs were prepared using the slurry method technique. This method generates liposomal vesicles with smaller size and a higher percentage of drug entrapment than those generated from conventional feed-line and thin-film methods [<xref rid="B31-pharmaceutics-17-00165" ref-type="bibr">31</xref>]. Different carbohydrate carriers were studied and the carrier that produces free-flowing granules (PLs) was selected. Mannitol-based PLs were spherical and smooth compared to sorbitol or microcrystalline cellulose-based ones [<xref rid="B28-pharmaceutics-17-00165" ref-type="bibr">28</xref>]. Consequently, mannitol was adopted as a carrier to support the lipid phase in this study.</p></sec><sec id="sec3dot2-pharmaceutics-17-00165"><title>3.2. Analysis of Factorial Design</title><p>Full factorial design is suitable to study the impact of all the factors simultaneously on the measured responses, as one can quantify the impact of the factors and their interactions on the measured responses [<xref rid="B41-pharmaceutics-17-00165" ref-type="bibr">41</xref>]. The results of the measured responses are represented in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. The selected model for each measured response was the one suggested by the design software. The significant and non-significant terms of the tested responses were differentiated, as mentioned in <xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>. The <italic toggle="yes">p</italic>-values less than 0.05 were recognized as significant, while other <italic toggle="yes">p</italic>-values higher than 0.05 were considered non-significant terms [<xref rid="B42-pharmaceutics-17-00165" ref-type="bibr">42</xref>]. <xref rid="pharmaceutics-17-00165-f001" ref-type="fig">Figure 1</xref> presents the 3-D response surface plots displaying the influence of the studied factors on the measured responses.</p><p>The R<sup>2</sup> values were found to be high and close to 1 (<xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>). These high values indicate a good correlation between both actual and predicted values of the measured responses (<xref rid="app1-pharmaceutics-17-00165" ref-type="app">Figure S1 in Supplementary Materials</xref>). It was observed that the predicted R<sup>2</sup> values were in reasonable agreement with the adjusted R<sup>2</sup> values since the difference between them was less than 0.2, as suggested by the design software, except in Y<sub>4</sub> and Y<sub>6</sub> responses for PDI and Q6h, respectively, (<xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>). The negative predicted R<sup>2</sup> values of PDI and Q6h implied that the overall mean may be a better predictor of these responses than the current model. This might be due to the fact that PDI and Q6h of the prepared PLs were not affected by studied factors. The adequate precision measures the signal to noise ratio, it was observed that it was greater than 4 in all responses and is desirable [<xref rid="B43-pharmaceutics-17-00165" ref-type="bibr">43</xref>] (<xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>). Thus, the selected models could be accurately used for the prediction of the measured responses and navigation of the design space [<xref rid="B44-pharmaceutics-17-00165" ref-type="bibr">44</xref>].</p><sec id="sec3dot2dot1-pharmaceutics-17-00165"><title>3.2.1. The Effect of Independent Variables on Product Yield (PY%; Y<sub>1</sub>)</title><p>The PY% was determined after the complete drying of the prepared PLs. The PY% was in the range of 88.6 &#x000b1; 2.19% to 98.8 &#x000b1; 0.45%, as shown in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. The impact of the independent factors on PY% is graphically illustrated in <xref rid="pharmaceutics-17-00165-f002" ref-type="fig">Figure 2</xref>. It was obvious that carrier/lipid phase ratio (A) had a significant impact on PY% (<italic toggle="yes">p</italic> &#x0003c; 0.05). There was a significant increase in PY% from 88.6 &#x000b1; 2.19% to 92.7 &#x000b1; 2.83% when the carrier/lipid phase ratio increased from 6:1 to 9:1 for PL2 and PL1, respectively. Similar results were reported by Omer et al. [<xref rid="B28-pharmaceutics-17-00165" ref-type="bibr">28</xref>], who demonstrated that the PY% decreased when increasing the lipid content, due to the adherence of lipids to the flask wall.</p><p>The amount of SG (B) had a significant effect on PY% (<italic toggle="yes">p</italic> &#x0003c; 0.05). The PY% for formulations containing SG was 98.5 &#x000b1; 1.74%, 97.3 &#x000b1; 0.77%, 98.8 &#x000b1; 0.45%, and 97.1 &#x000b1; 1.15% for PL5, PL6, PL7, and PL8, respectively, compared to the corresponding SG-free formulations: PL1 (92.7 &#x000b1; 2.83%), PL2 (88.6 &#x000b1; 2.19%), PL3 (91.7 &#x000b1; 1.93%), and PL4 (90.2 &#x000b1; 2.61%), respectively. SG can enhance the interaction between phospholipids and mannitol, resulting in a more uniform coating and formation of PLs. This uniform coating reduces the adherence of lipids to the flask, minimizing the material loss.</p><p>Phospholipid type (C) had a non-significant effect on PY% (<italic toggle="yes">p</italic> &#x0003e; 0.05) as clear in PL1 (92.7 &#x000b1; 2.83%) and its corresponding formulation PL3 (91.7 &#x000b1; 1.93%); the same was seen for PL2 (88.6 &#x000b1; 2.19%) and its corresponding formulation PL4 (90.2 &#x000b1; 2.61%).</p></sec><sec id="sec3dot2dot2-pharmaceutics-17-00165"><title>3.2.2. The Effect of Independent Variables on Entrapment Efficiency (EE%; Y<sub>2</sub>)</title><p>The drug was encapsulated in liposomal vesicles after aqueous hydration of the prepared PLs. The EE% of the prepared formulations ranged from 71.8 &#x000b1; 2.01% to 96.1 &#x000b1; 0.51%, as depicted in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. The impact of the independent factors on EE% is graphically illustrated in <xref rid="pharmaceutics-17-00165-f003" ref-type="fig">Figure 3</xref>. It was clear that carrier/lipid phase ratio (A) had a significant influence on EE% (<italic toggle="yes">p</italic> &#x0003c; 0.05). When this ratio increased from 6:1 [PL2 (83.4 &#x000b1; 0.81%), PL4 (88.9 &#x000b1; 0.94%), PL6 (88.7 &#x000b1; 1.40%), and PL8 (96.1 &#x000b1; 0.51%)] to 9:1 [PL1 (71.8 &#x000b1; 2.01%), PL3 (81.2 &#x000b1; 2.17%), PL5 (81.7 &#x000b1; 1.32%), and PL7 (87.9 &#x000b1; 0.75%)] there was a significant reduction in the EE% of the corresponding formulations, respectively. The lipophilic characteristics of the drug might explain the increased EE% upon the increasing concentration of lipids. These results are consistent with previous reports revealing that increasing the total lipid concentration favors the formation of multilamellar vesicles (MLV), and thereby increases the trapped volume for the encapsulated drug within liposomes [<xref rid="B45-pharmaceutics-17-00165" ref-type="bibr">45</xref>]. Similar results were reported by Omer et al. [<xref rid="B28-pharmaceutics-17-00165" ref-type="bibr">28</xref>], who demonstrated that the EE% of salbutamol sulfate increased when increasing the lipid proportion in the formulation.</p><p>The percentage of drug encapsulated in liposomal vesicles may depend on many factors including liposomal size, liposome bilayers, and the effect of carbohydrate carrier on the packing pattern of liposome bilayers. There is a direct relationship between the drug leakage from the vesicles and the carrier concentration. The increase in carrier concentration resulted in a consequent decrease in the liposomal size; a small space within the liposome is available for drug entrapment that could explain the reduction in entrapment efficiency [<xref rid="B46-pharmaceutics-17-00165" ref-type="bibr">46</xref>].</p><p>The amount of SG (B) had a significant increasing effect on EE% (<italic toggle="yes">p</italic> &#x0003c; 0.05). The formulations containing SG [PL5 (81.7 &#x000b1; 1.32%), PL6 (88.7 &#x000b1; 1.40%), PL7 (87.9 &#x000b1; 0.75%), and PL8 (96.1 &#x000b1; 0.51%)] had higher EE% than the corresponding SG-free formulations [PL1 (71.8 &#x000b1; 2.01%), PL2 (83.4 &#x000b1; 0.81%), PL3 (81.2 &#x000b1; 2.17%), and PL4 (88.9 &#x000b1; 0.94%)], respectively. SG creates a hydrophobic environment inside the bilayer vesicles, helping in the encapsulation and retention of hydrophobic drugs. It can also form an intermolecular hydrogen bond with IVM, helping to keep it within the liposomal vesicles and reduce its leakage.</p><p>The EE% values are also altered by varying lipid composition [<xref rid="B47-pharmaceutics-17-00165" ref-type="bibr">47</xref>]. This variation may be a result of interaction between IVM and the head group of phospholipids with different lengths of carbon chain. The formulations based on DPPC [PL3 (81.2 &#x000b1; 2.17%), PL4 (88.9 &#x000b1; 0.94%), PL7 (87.9 &#x000b1; 0.75%), and PL8 (96.1 &#x000b1; 0.51%)] showed higher entrapment than the corresponding SPC based ones [PL1 (71.8 &#x000b1; 2.01%), PL2 (83.4 &#x000b1; 0.81%), PL5 (81.7 &#x000b1; 1.32%), and PL6 (88.7 &#x000b1; 1.40%)], respectively. It might be due to the well stabilization of liposomal membrane created by increasing the fatty acid chain length as in DPPC so that drug leakage from vesicles is reduced, leading to high entrapment values [<xref rid="B48-pharmaceutics-17-00165" ref-type="bibr">48</xref>].</p></sec><sec id="sec3dot2dot3-pharmaceutics-17-00165"><title>3.2.3. The Effect of Independent Variables on Particle Size (PS; Y<sub>3</sub>)</title><p>Analysis of the size of liposomes was carried out upon hydration of the prepared PLs. The mean PS of the liposomal vesicles was in the range of 330.1 &#x000b1; 55.65 nm to 1801.6 &#x000b1; 45.61 nm, as clear in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. The impact of independent factors on PS is graphically illustrated in <xref rid="pharmaceutics-17-00165-f004" ref-type="fig">Figure 4</xref>.</p><p>Carrier/lipid phase ratio (A) had a non-significant effect on the PS of liposomal vesicles (<italic toggle="yes">p</italic> &#x0003e; 0.05), as clear in PL3 (1358.3 &#x000b1; 95.84 nm), and its corresponding formulation PL4 (1462.3 &#x000b1; 28.86 nm); the same was true for PL5 (490.3 &#x000b1; 21.75 nm) and its corresponding formulation PL6 (523.7 &#x000b1; 25.86 nm).</p><p>The amount of SG (B) had a significant effect on PS (<italic toggle="yes">p</italic> &#x0003c; 0.05). The PS of SG-based formulations were [PL5 (490.3 &#x000b1; 21.75), PL6 (523.7 &#x000b1; 25.86), PL7 (1695.3 &#x000b1; 46.76), and PL8 (1801.6 &#x000b1; 45.61 nm)] which was higher than the corresponding SG-free formulations [PL1 (330.1 &#x000b1; 55.65), PL2 (385.7 &#x000b1; 49.18), PL3 (1358.3 &#x000b1; 95.84), and PL4 (1462.3 &#x000b1; 28.86 nm)], respectively. The increase in the size of vesicles with the addition of SG could be related to its possible placement within liposomal vesicles near the head groups of phosphatidyl choline (PC) at the interface between the glycerol groups and the nonpolar lipid chains [<xref rid="B49-pharmaceutics-17-00165" ref-type="bibr">49</xref>]. This position resulted in an increase in the average distance among the PC molecules that constituted the bilayer of the vesicles.</p><p>Phospholipid type (C) also had a significant effect on PS (<italic toggle="yes">p</italic> &#x0003c; 0.05). The PS of DPPC based formulations [PL3 (1358.3 &#x000b1; 95.84), PL4 (1462.3 &#x000b1; 28.86), PL7 (1695.3 &#x000b1; 46.76), and PL8 (1801.6 &#x000b1; 45.61 nm)] were higher than the corresponding SPC based ones [PL1 (330.1 &#x000b1; 55.65), PL2 (385.7 &#x000b1; 49.18), PL5 (490.3 &#x000b1; 21.75), and PL6 (523.7 &#x000b1; 25.86 nm)], respectively (<xref rid="app1-pharmaceutics-17-00165" ref-type="app">Figure S2a,b in Supplementary Materials</xref>). This may be attributed to the higher hydrophobicity of longer acyl chains in DPPC and repulsive interactions between water molecules at the interface, resulting in aggregation of vesicles [<xref rid="B47-pharmaceutics-17-00165" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot2dot4-pharmaceutics-17-00165"><title>3.2.4. The Effect of Independent Variables on Polydispersity Index (PDI; Y<sub>4</sub>)</title><p>The PDI is a measure of the width of unimodal size distributions. According to the FDA, PDI is an essential parameter that should usually be considered when evaluating the liposomal preparations [<xref rid="B27-pharmaceutics-17-00165" ref-type="bibr">27</xref>]. A value of 0 indicates homogenous dispersion, while a value of 1 indicates an entirely heterogeneous polydisperse population [<xref rid="B43-pharmaceutics-17-00165" ref-type="bibr">43</xref>]. The mean PDI of the liposomal vesicles was in the range of 0.205 &#x000b1; 0.06 to 0.603 &#x000b1; 0.03 for all formulations, without extreme readings, as shown in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. Factorial analysis showed that the independent variables&#x02014;carrier/lipid phase ratio (A), SG amount (B), phospholipid type (C)&#x02014;and their interactions showed non-significant effects on PDI with <italic toggle="yes">p</italic>-values &#x0003e; 0.05, as represented in <xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot2dot5-pharmaceutics-17-00165"><title>3.2.5. The Effect of Independent Variables on Zeta Potential (ZP; Y<sub>5</sub>)</title><p>The ZP is the electrostatic charge of the particle surface; it has a major role in determining the colloidal stability by a repulsive energy barrier which inhibits particles aggregation. The ZP of all formulations is determined after hydration and the results are summarized in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. The average of ZP was found to be in the range of &#x02212;18.2 &#x000b1; 0.60 mV to &#x02212;50.1 &#x000b1; 1.80 mV. Liposomal vesicles exhibit negative potential irrespective of formulation composition due to the negative charge of the polar head group of the phospholipids. A high negative net charge prevents vesicles aggregation, achieving homogenous suspension [<xref rid="B37-pharmaceutics-17-00165" ref-type="bibr">37</xref>]. The impact of the independent factors on ZP is graphically illustrated in <xref rid="pharmaceutics-17-00165-f005" ref-type="fig">Figure 5</xref>.</p><p>It is clear from the results that both carrier/lipid phase ratio (A) and SG amount (B) had a non-significant effect on ZP of liposomal vesicles (<italic toggle="yes">p</italic> &#x0003e; 0.05). On the other hand, phospholipid type (C) influenced ZP significantly (<italic toggle="yes">p</italic> &#x0003c; 0.05). The ZP (as an absolute value) of DPPC based formulations [PL3 (&#x02212;25.4 &#x000b1; 1.35), PL4 (&#x02212;18.2 &#x000b1; 0.60), PL7 (&#x02212;20.1 &#x000b1; 1.40), and PL8 (&#x02212;19.7 &#x000b1; 0.73 mV)] were lower than those of the corresponding formulations with SPC [PL1 (&#x02212;42.4 &#x000b1; 4.80), PL2 (&#x02212;50.1 &#x000b1; 1.80), PL5 (&#x02212;40.1 &#x000b1; 1.04) and PL6 (&#x02212;42.4 &#x000b1; 1.10 mV)], respectively (<xref rid="app1-pharmaceutics-17-00165" ref-type="app">Figure S2c,d in Supplementary Materials</xref>). The negative charge was greater in case of SPC-based formulations because SPC contains unsaturated fatty acids, the carboxylic acid groups of these unsaturated fatty acids potentially increasing the negative charge.</p></sec><sec id="sec3dot2dot6-pharmaceutics-17-00165"><title>3.2.6. The Effect of Independent Variables on Drug Released After 6 h (Q6h; Y<sub>6</sub>)</title><p>Reconstituted liposomes were subjected to an in vitro release investigation across a dialysis membrane in order to determine the impact of the investigated independent factors on the drug release. The pH of the dissolution medium was selected to simulate the pH of alveoli; the conducting airways are lined with a mucus gel-aqueous sol complex of up to 100 &#x000b5;m in depth called air surface liquid (ASL), the pH of this mucosal layer is acidic compared to blood pH [<xref rid="B50-pharmaceutics-17-00165" ref-type="bibr">50</xref>]. Sodium lauryl sulfate was added to enhance the release of IVM, considering the ability of surfactants to accelerate this process due to the reduction in the interfacial tension and micellar solubilization properties [<xref rid="B10-pharmaceutics-17-00165" ref-type="bibr">10</xref>]. Drug release after 6 h (Q6h%) of the prepared formulations ranged from 80.95 &#x000b1; 1.36% to 88.79 &#x000b1; 2.03%, as depicted in <xref rid="pharmaceutics-17-00165-t002" ref-type="table">Table 2</xref>. As clear from the results, the studied factors and their interactions had non-significant effects on Q6h, with <italic toggle="yes">p</italic>-values &#x0003e; 0.05, as represented in <xref rid="pharmaceutics-17-00165-t003" ref-type="table">Table 3</xref>.</p><p>The release profiles for all the developed PLs exhibited relatively similar drug release characteristics at the end of 6 h (<xref rid="app1-pharmaceutics-17-00165" ref-type="app">Figure S3 in Supplementary Materials</xref>), a typical biphasic pattern was observed with an initial rapid phase followed by a slow sustained phase. The burst release of the drug due to the presence of unentrapped drug in the outer layers of liposomes is expected to be responsible for the initial rapid phase [<xref rid="B51-pharmaceutics-17-00165" ref-type="bibr">51</xref>]. The PLs have the ability to convert the physical nature of the loaded lipophilic drugs from the crystalline state into an amorphous state, resulting in an increased solubility of the entrapped lipophilic drugs inside PLs. In addition, the hydrophilic nature of the mannitol which facilitates the quick hydration of PLs to transform into liposomes might be one of the causes for enhancing the drug release [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>].</p></sec><sec id="sec3dot2dot7-pharmaceutics-17-00165"><title>3.2.7. Kinetic Study of Drug Release</title><p>IVM release mechanism from PLs formulations was studied using in vitro release data from various mathematical models, as shown in <xref rid="pharmaceutics-17-00165-t004" ref-type="table">Table 4</xref>. The model that had the highest R<sup>2</sup> value was Korsmeyer&#x02013;Peppas model, making it the most suitable option for describing the process of IVM release. The Korsmeyer&#x02013;Peppas model n value was less than 0.5 for all formulations. This could indicate the fitness of drug release to quasi-Fickian diffusion mechanism (case I transport) [<xref rid="B52-pharmaceutics-17-00165" ref-type="bibr">52</xref>].</p></sec></sec><sec id="sec3dot3-pharmaceutics-17-00165"><title>3.3. Optimization Technique</title><p>The aim of the optimization step was to achieve the maximum PY%, EE%, ZP (as absolute value), and Q6h and the minimum PS and PDI, as previously prescribed in <xref rid="pharmaceutics-17-00165-t001" ref-type="table">Table 1</xref>. The optimized formulation suggested by the design software was PL6, which met these criteria with a high desirability value (0.830). The predicted and observed responses of PL6 were compared as shown in <xref rid="pharmaceutics-17-00165-t005" ref-type="table">Table 5</xref> to validate the experiment. The models&#x02019; validity and the design&#x02019;s good predictability were confirmed by the high correlation between the observed and predicted values [<xref rid="B36-pharmaceutics-17-00165" ref-type="bibr">36</xref>]. The aim of this study is to investigate the activity of IVM-loaded PLs and SG modified IVM-loaded PLs in IBV-infected ECEs. Subsequently, PL6 and its corresponding formulation (PL2) were selected as the optimized formulations for further investigations.</p></sec><sec id="sec3dot4-pharmaceutics-17-00165"><title>3.4. Characterization of the Selected IVM-Loaded PLs Formulations</title><sec id="sec3dot4dot1-pharmaceutics-17-00165"><title>3.4.1. Scanning Electron Microscopy (SEM)</title><p>The SEM photographs revealed that the surface morphology of mannitol in the selected formulations (PL2 and PL6) was different from pure mannitol. The crystalline form of mannitol which presented in its pure sample was not clear in the selected formulations due to deposition of phospholipid on its surface [<xref rid="B33-pharmaceutics-17-00165" ref-type="bibr">33</xref>]. Observation under digital microscope revealed that the proliposomal particles were rapidly converted to liposomes within a few minutes following contact with water, as presented in <xref rid="pharmaceutics-17-00165-f006" ref-type="fig">Figure 6</xref>c.</p></sec><sec id="sec3dot4dot2-pharmaceutics-17-00165"><title>3.4.2. DSC Analysis</title><p>The physical state of the drug in the proliposomal formulation was studied using DSC, where any shift or disappearance of peaks could indicate the alteration in the crystallinity of the drug [<xref rid="B34-pharmaceutics-17-00165" ref-type="bibr">34</xref>,<xref rid="B53-pharmaceutics-17-00165" ref-type="bibr">53</xref>]. The DSC thermograms of pure IVM, SG, SPC, cholesterol, mannitol, selected formulations (PL2 and PL6), and the blank formulation are illustrated in <xref rid="pharmaceutics-17-00165-f007" ref-type="fig">Figure 7</xref>a,b. Pure IVM and SG showed endothermic peaks at 158.69 &#x000b0;C and 76.69 &#x000b0;C, respectively, corresponding to their crystalline state at their melting point temperature [<xref rid="B54-pharmaceutics-17-00165" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-17-00165" ref-type="bibr">55</xref>]. The characteristic peak of SPC was at 187.42 &#x000b0;C, corresponding to its melting temperature (transition from gel state to liquid crystal state) [<xref rid="B42-pharmaceutics-17-00165" ref-type="bibr">42</xref>]. The characteristic peak of cholesterol was at 144.47 &#x000b0;C. The sharp characteristic peak of mannitol was at 167.66 &#x000b0;C, corresponding to its crystalline state at this melting point [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>]; this peak was preserved in the thermograms of the blank formulation and selected formulations (PL2 and PL6), signifying the maintenance of the crystalline state of mannitol in PLs formulations [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>]. The DSC thermograms of the selected formulations showed no representative peak of IVM, suggesting its transformation from crystalline state to amorphous form or the dissolution of the drug in the molten mass [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>].</p></sec><sec id="sec3dot4dot3-pharmaceutics-17-00165"><title>3.4.3. FTIR</title><p>FTIR analysis was conducted to investigate the possible interactions between IVM and excipients based on characteristic drug peaks&#x02019; absence or shifts [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>,<xref rid="B33-pharmaceutics-17-00165" ref-type="bibr">33</xref>]. The FTIR spectra of pure IVM, SG, SPC, cholesterol, mannitol, PL2, PL6, and the blank formulation are presented in <xref rid="pharmaceutics-17-00165-f008" ref-type="fig">Figure 8</xref>. FTIR spectrum of pure IVM displayed characteristic bands at 3450.99 cm<sup>&#x02212;1</sup> (O-H stretching), 2931.27 cm<sup>&#x02212;1</sup> (C-H stretching), 1732.73 cm<sup>&#x02212;1</sup> and 1690.66 cm<sup>&#x02212;1</sup> (C=O stretching), 1458.96 cm<sup>&#x02212;1</sup> (O-H bending), and 1394.64 cm<sup>&#x02212;1</sup> (C-O stretching). The FTIR spectrum of mannitol showed characteristic peaks at 3290.83 cm<sup>&#x02212;1</sup> (O-H stretching of alcohol), 1082.83 and 1019.23 cm<sup>&#x02212;1</sup> (C-O stretching of alcohol), 929.521 cm<sup>&#x02212;1</sup> and 879.381 cm<sup>&#x02212;1</sup> (C-H out of plane bending). The FTIR spectrum of SPC showed characteristic peaks at 2924.52 cm<sup>&#x02212;1</sup> and 2855.1 cm<sup>&#x02212;1</sup> (stretching vibration absorption of CH2), 1740.44 cm<sup>&#x02212;1</sup> (C=O stretching vibration of carboxylic acid). Cholesterol showed principal absorption peaks at 2925.48 cm<sup>&#x02212;1</sup>, corresponding to the C-H aliphatic stretching and 1402.74 cm<sup>&#x02212;1</sup>, corresponding to the plane bending for CH<sub>3</sub>, OH. On comparing the FTIR spectrum of blank formulation and these of the selected formulations, the results confirmed the absence of additional peaks and no chemical interaction between IVM and other components of PLs [<xref rid="B25-pharmaceutics-17-00165" ref-type="bibr">25</xref>,<xref rid="B56-pharmaceutics-17-00165" ref-type="bibr">56</xref>]. This was in great alignment with what was found by Janga et al. [<xref rid="B51-pharmaceutics-17-00165" ref-type="bibr">51</xref>].</p></sec><sec id="sec3dot4dot4-pharmaceutics-17-00165"><title>3.4.4. Stability Studies</title><p>The results of the stability studies for the selected formulations (PL2 and PL6) are presented in <xref rid="pharmaceutics-17-00165-f009" ref-type="fig">Figure 9</xref>. No signs of crystallization were observed under an optical microscope, the PLs were free flowing without any agglomeration when detected visually and the formation of the liposomal vesicles was rapid upon hydration. For PL2 there was a non-significant difference (<italic toggle="yes">p</italic> &#x0003e; 0.05) in the EE%, PS, and ZP for samples stored at 4 &#x000b1; 1 &#x000b0;C and 25 &#x000b1; 1 &#x000b0;C compared to the freshly prepared one at all time intervals (1, 2 and 3 months), which indicates its stability in storage at room temperature and refrigerated conditions.</p><p>There was a non-significant difference (<italic toggle="yes">p</italic> &#x0003e; 0.05) in the EE%, PS, and ZP for PL6 stored at 4 &#x000b1; 1 &#x000b0;C compared to the freshly prepared one at all time intervals (1, 2 and 3 months). On the other hand, the differences in PS and EE% were significant at each time interval, and in ZP at 3 months only for samples stored at 25 &#x000b1; 1 &#x000b0;C; this significant difference may be related to SG as it requires lower temperatures to be stable. So, we recommend storing the prepared formulations in refrigerated conditions.</p></sec></sec><sec id="sec3dot5-pharmaceutics-17-00165"><title>3.5. Investigation of the Anti-Viral Activity Against IBV</title><sec id="sec3dot5dot1-pharmaceutics-17-00165"><title>3.5.1. Toxicity Study</title><p>The MNTC was calculated for pure IVM, PL2, and PL6 in ECEs. It was identified as the concentration that yielded more than 50% survival or that exhibited signs of lesions not exceeding 50% of inoculated embryos. Macroscopic lesions of embryos are shown in <xref rid="pharmaceutics-17-00165-f010" ref-type="fig">Figure 10</xref>. For pure IVM, ECEs inoculated with 400 &#x000b5;M and 200 &#x000b5;M showed 66.7% and 33.3% survival, with 100% lesions in both concentrations. Meanwhile, ECEs inoculated with 100 &#x000b5;M showed 33.3% lesions and 100% survival. Absence of death and lesions were observed in ECEs inoculated with lower concentrations. ECEs inoculated with PL2 exhibited 100% and 66.7% survival for those that received 400 &#x000b5;M and 200 &#x000b5;M, respectively, with 100% and 33.3% lesions, respectively, and the absence of death and lesions in ECEs inoculated with lower concentrations. It was observed that the liposomal vesicles of IVM has lower toxicity in ECEs than pure IVM, and this result was in accordance with Croci et al. [<xref rid="B6-pharmaceutics-17-00165" ref-type="bibr">6</xref>]. Drugs encapsulated in liposomes are released gradually and in a controlled manner. This avoids the sudden increase in drug concentration in the bloodstream that often occurs with free drugs, thereby reducing the risk of toxicity. ECEs inoculated with 400 &#x000b5;M and 200 &#x000b5;M of PL6 exhibited 66.7% for both survival and lesions. Meanwhile, ECEs inoculated with 100 &#x000b5;M showed 33.3% lesions and 100% survival and there was no death and lesions in ECEs inoculated with further lower concentrations.</p></sec><sec id="sec3dot5dot2-pharmaceutics-17-00165"><title>3.5.2. Assay of Anti-Viral Activity</title><p>The mortality percentage of ECEs was calculated five days post-inoculation and the results were analyzed using GraphPad Prism version 8. As presented in <xref rid="pharmaceutics-17-00165-f011" ref-type="fig">Figure 11</xref>, the positive control group showed a significantly high percentage of mortality in comparison with the negative control group after five days of inoculation with IBV. There is a reduction in the percentage of mortality of IBV-infected ECEs inoculated with pure IVM in comparison with positive control group and this reduction was significant at 50 &#x000b5;M (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>Inoculation with PL2 resulted in a greater reduction in the percentage of mortality of IBV-infected ECEs compared with those inoculated with pure IVM at all studied doses, this may be due to high cellular uptake of liposomal vesicles of IVM in comparison with free IVM. It was also observed that there was a significant reduction in the percentage of mortality of IBV-infected ECEs at all studied doses of PL2 compared with the positive control group (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p><p>On the other hand, there was a non-significant difference in the percentage of mortality of PL6-inoculated IBV-infected ECEs compared with the positive control group (<italic toggle="yes">p</italic> &#x0003e; 0.05). Impaired fitting on the receptor due to masking the functional group of IVM by the steric hindrance of SG may be the reason for the higher mortality percentage in PL6 receiving, IBV-infected ECEs compared with that in PL2-receiving, IBV-infected ECEs.</p><p>Macroscopic visualization of the embryos showed an absence of curling and dwarfing in IBV-infected ECEs treated with PL2, as presented in <xref rid="pharmaceutics-17-00165-f012" ref-type="fig">Figure 12</xref>A; there was a statistical significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.001) in the lengths of ECEs in the positive control group compared to those of the negative control group. On the other hand, it was observed that the lengths of IBV-infected ECEs treated with PL2 at all studied doses were not significantly differed from those of the negative group, but there was a statistically significant difference (<italic toggle="yes">p</italic> &#x0003c; 0.001) in comparison with those of the positive control group: <xref rid="pharmaceutics-17-00165-f012" ref-type="fig">Figure 12</xref>B.</p><p>In addition, the viral load was quantified (<xref rid="pharmaceutics-17-00165-f013" ref-type="fig">Figure 13</xref>); there is a significant reduction in the copies of IBV 72 h post-inoculation in the pure IVM-treated group in comparison with the positive control group (<italic toggle="yes">p</italic> &#x0003c; 0.01). The group treated with PL2 exhibited further reduction in IBV&#x02019;s copies (<italic toggle="yes">p</italic> &#x0003c; 0.05) in comparison with IVM-treated group and this reduction was more significant when compared to positive control group (<italic toggle="yes">p</italic> &#x0003c; 0.001). On the other hand, there is a non-significant difference in copies of IBV in the PL6-treated group in comparison with the pure IVM-treated group, but this difference was significant when compared to the positive control group (<italic toggle="yes">p</italic> &#x0003c; 0.01).</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00165"><title>4. Conclusions</title><p>In this study, IVM-loaded PLs were fabricated, characterized, and optimized using a 2<sup>3</sup> full factorial design. Furthermore, the selected formulations were investigated for their efficacy against IBV. All of the prepared formulations exhibited high EE%, ranging from 71.8 &#x000b1; 2.01% to 96.1 &#x000b1; 0.51%, adequate repulsive force to improve physical liposomal stability, and cumulative release values ranging from 80.95 &#x000b1; 1.36% to 88.79 &#x000b1; 2.03%. For three months, the chosen formulations demonstrated good stability. Additionally, research into the anti-viral action against IBV-infected ECEs revealed a much lower mortality rate for ECEs with PL2 inoculations compared to IBV-infected ECEs that did not receive any treatment (positive control). These findings demonstrated that loading IVM into PLs increased IVM&#x02019;s anti-viral action against IBV.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are thankful to the Deanship of Graduate Studies and Scientific Research at Najran University for funding this work under the Easy Funding Program grant code NU/EFP/SERC/13/167. The authors are also very thankful to the virology lab at the Faculty of Veterinary Medicine, Zagazig University for providing research lab facilities to perform the anti-viral study. </p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00165"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020165/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020165/s1</uri>, Figure S1: Linear correlation plots between actual and predicted values for (a) Y<sub>1</sub> response, (b) Y<sub>2</sub> response, (c) Y<sub>3</sub> response, (d) Y<sub>4</sub> response, (e) Y<sub>5</sub> response, (f) Y<sub>6</sub> response. Figure S2: PS and ZP of IVM-loaded PLs formulations. (a) PS of SPC based IVM-Loaded PLs, (b) PS of DPPC based IVM-Loaded PLs, (c) ZP of SPC based IVM-Loaded PLs, (d) ZP of DPPC based IVM-Loaded PLs. Figure S3: In vitro drug release profiles of IVM-loaded PLs formulations (n = 3 &#x000b1; SD).</p><supplementary-material id="pharmaceutics-17-00165-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00165-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.M.A., S.A.S., S.M.G.M. and M.M.A.; methodology, A.M.A., S.A.S. and S.M.G.M.; software, A.M.A.; validation, H.S.A., H.M.E.-N., M.H.A. and M.M.A.; formal analysis, A.M.A.; investigation, A.M.A. and S.A.S.; resources, A.M.A.; data curation, A.M.A. and S.A.S.; writing&#x02014;original draft preparation, A.M.A.; writing&#x02014;review and editing, A.M.A., S.A.S., S.M.G.M., M.M.A. and H.M.E.-N.; visualization, M.H.A.; supervision, H.M.E.-N., S.A.S. and M.M.A.; funding acquisition, M.H.A. and H.S.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) guidelines of the Faculty of Pharmacy, Zagazig University (Approval number: ZU-IACUC/3/F/438/2022).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available in this article and the <xref rid="app1-pharmaceutics-17-00165" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00165"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavanagh</surname><given-names>D.</given-names></name>
</person-group><article-title>Coronavirus Avian Infectious Bronchitis Virus</article-title><source>Vet. Res.</source><year>2007</year><volume>38</volume><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1051/vetres:2006055</pub-id><pub-id pub-id-type="pmid">17296157</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00165"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ignjatovic</surname><given-names>J.</given-names></name>
<name><surname>Sapats</surname><given-names>S.</given-names></name>
</person-group><article-title>Avian Infectious Bronchitis Virus</article-title><source>Rev. Sci. Tech.</source><year>2000</year><volume>19</volume><fpage>493</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.20506/rst.19.2.1228</pub-id><pub-id pub-id-type="pmid">10935276</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00165"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhuiyan</surname><given-names>S.A.</given-names></name>
<name><surname>Amin</surname><given-names>Z.</given-names></name>
<name><surname>Rodrigues</surname><given-names>K.F.</given-names></name>
<name><surname>Saallah</surname><given-names>S.</given-names></name>
<name><surname>Shaarani</surname><given-names>S.</given-names></name>
<name><surname>Sarker</surname><given-names>S.</given-names></name>
<name><surname>Siddiquee</surname><given-names>S.</given-names></name>
</person-group><article-title>Veterinary Sciences Infectious Bronchitis Virus (Gammacoronavirus) in Poultry Farming: Vaccination, Immune Response and Measures for Mitigation</article-title><source>Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>273</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci8110273</pub-id><pub-id pub-id-type="pmid">34822646</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00165"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hellwig</surname><given-names>M.D.</given-names></name>
<name><surname>Maia</surname><given-names>A.</given-names></name>
</person-group><article-title>A COVID-19 Prophylaxis? Lower Incidence Associated with Prophylactic Administration of Ivermectin</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>57</volume><fpage>106248</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106248</pub-id><pub-id pub-id-type="pmid">33259913</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00165"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Popp</surname><given-names>M.</given-names></name>
<name><surname>Reis</surname><given-names>S.</given-names></name>
<name><surname>Schie&#x000df;er</surname><given-names>S.</given-names></name>
<name><surname>Hausinger</surname><given-names>R.I.</given-names></name>
<name><surname>Stegemann</surname><given-names>M.</given-names></name>
<name><surname>Metzendorf</surname><given-names>M.-I.</given-names></name>
<name><surname>Kranke</surname><given-names>P.</given-names></name>
<name><surname>Meybohm</surname><given-names>P.</given-names></name>
<name><surname>Skoetz</surname><given-names>N.</given-names></name>
<name><surname>Weibel</surname><given-names>S.</given-names></name>
</person-group><article-title>Ivermectin for Preventing and Treating COVID-19 (Review)</article-title><source>Cochrane Database Syst. Rev.</source><year>2022</year><volume>2022</volume><fpage>CD015017</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD015017.pub3</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00165"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Croci</surname><given-names>R.</given-names></name>
<name><surname>Bottaro</surname><given-names>E.</given-names></name>
<name><surname>Chan</surname><given-names>K.W.K.</given-names></name>
<name><surname>Watanabe</surname><given-names>S.</given-names></name>
<name><surname>Pezzullo</surname><given-names>M.</given-names></name>
<name><surname>Mastrangelo</surname><given-names>E.</given-names></name>
<name><surname>Nastruzzi</surname><given-names>C.</given-names></name>
</person-group><article-title>Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin</article-title><source>Int. J. Biomater.</source><year>2016</year><volume>2016</volume><elocation-id>8043983</elocation-id><pub-id pub-id-type="doi">10.1155/2016/8043983</pub-id><pub-id pub-id-type="pmid">27242902</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00165"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahnashi</surname><given-names>M.H.</given-names></name>
<name><surname>Mahmoud</surname><given-names>A.M.</given-names></name>
<name><surname>Alkahtani</surname><given-names>S.A.</given-names></name>
<name><surname>El-wekil</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Ivermectin Detection Using Ag@ B, S Co-Doped Reduced Graphene Oxide Nanohybrid</article-title><source>J. Alloys Compd.</source><year>2021</year><volume>871</volume><fpage>159627</fpage><pub-id pub-id-type="doi">10.1016/j.jallcom.2021.159627</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-00165"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crump</surname><given-names>A.</given-names></name>
<name><surname>&#x0014c;mura</surname><given-names>S.</given-names></name>
</person-group><article-title>Ivermectin, &#x02018;Wonder Drug&#x02019; from Japan: The Human Use Perspective</article-title><source>Proc. Jpn. Acad.</source><year>2011</year><volume>87</volume><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2183/pjab.87.13</pub-id><pub-id pub-id-type="pmid">21321478</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00165"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Awad</surname><given-names>H.</given-names></name>
<name><surname>Rawas-Qalaji</surname><given-names>M.</given-names></name>
<name><surname>El Hosary</surname><given-names>R.</given-names></name>
<name><surname>Jagal</surname><given-names>J.</given-names></name>
<name><surname>Ahmed</surname><given-names>I.S.</given-names></name>
</person-group><article-title>Formulation and Optimization of Ivermectin Nanocrystals for Enhanced Topical Delivery</article-title><source>Int. J. Pharm. X</source><year>2023</year><volume>6</volume><fpage>100210</fpage><pub-id pub-id-type="doi">10.1016/j.ijpx.2023.100210</pub-id><pub-id pub-id-type="pmid">37727680</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00165"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Starkloff</surname><given-names>W.J.</given-names></name>
<name><surname>Bucal&#x000e1;</surname><given-names>V.</given-names></name>
<name><surname>Palma</surname><given-names>S.D.</given-names></name>
<name><surname>Vidal</surname><given-names>N.L.G.</given-names></name>
</person-group><article-title>Design and in Vitro Characterization of Ivermectin Nanocrystals Liquid Formulation Based on a Top-down Approach</article-title><source>Pharm. Dev. Technol.</source><year>2017</year><volume>22</volume><fpage>809</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1080/10837450.2016.1200078</pub-id><pub-id pub-id-type="pmid">27346432</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00165"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varghese</surname><given-names>F.S.</given-names></name>
<name><surname>Kaukinen</surname><given-names>P.</given-names></name>
<name><surname>Gl&#x000e4;sker</surname><given-names>S.</given-names></name>
<name><surname>Bespalov</surname><given-names>M.</given-names></name>
<name><surname>Hanski</surname><given-names>L.</given-names></name>
<name><surname>Wennerberg</surname><given-names>K.</given-names></name>
<name><surname>K&#x000fc;mmerer</surname><given-names>B.M.</given-names></name>
<name><surname>Ahola</surname><given-names>T.</given-names></name>
</person-group><article-title>Discovery of Berberine, Abamectin and Ivermectin as Antivirals against Chikungunya and Other Alphaviruses</article-title><source>Antivir. Res.</source><year>2016</year><volume>126</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.12.012</pub-id><pub-id pub-id-type="pmid">26752081</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00165"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lv</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Dang</surname><given-names>R.</given-names></name>
<name><surname>Qiu</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Yan</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>Ivermectin Inhibits DNA Polymerase UL42 of Pseudorabies Virus Entrance into the Nucleus and Proliferation of the Virus In Vitro and Vivo</article-title><source>Antivir. Res.</source><year>2018</year><volume>159</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.09.010</pub-id><pub-id pub-id-type="pmid">30266338</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00165"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.N.Y.</given-names></name>
<name><surname>Atkinson</surname><given-names>S.C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>A.</given-names></name>
<name><surname>Bogoyevitch</surname><given-names>M.A.</given-names></name>
<name><surname>Borg</surname><given-names>N.A.</given-names></name>
<name><surname>Jans</surname><given-names>D.A.</given-names></name>
</person-group><article-title>The Broad Spectrum Antiviral Ivermectin Targets the Host Nuclear Transport Importin &#x003b1;/&#x00392;1 Heterodimer</article-title><source>Antivir. Res.</source><year>2020</year><volume>177</volume><fpage>104760</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104760</pub-id><pub-id pub-id-type="pmid">32135219</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00165"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caly</surname><given-names>L.</given-names></name>
<name><surname>Druce</surname><given-names>J.D.</given-names></name>
<name><surname>Catton</surname><given-names>M.G.</given-names></name>
<name><surname>Jans</surname><given-names>D.A.</given-names></name>
<name><surname>Wagstaff</surname><given-names>K.M.</given-names></name>
</person-group><article-title>The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro</article-title><source>Antivir. Res.</source><year>2020</year><volume>178</volume><fpage>104787</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmid">32251768</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00165"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bryant</surname><given-names>A.</given-names></name>
<name><surname>Lawrie</surname><given-names>T.A.</given-names></name>
<name><surname>Dowswell</surname><given-names>T.</given-names></name>
<name><surname>Fordham</surname><given-names>E.J.</given-names></name>
<name><surname>Mitchell</surname><given-names>S.</given-names></name>
<name><surname>Hill</surname><given-names>S.R.</given-names></name>
<name><surname>Tham</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines</article-title><source>Am. J. Ther.</source><year>2021</year><volume>28</volume><fpage>e434</fpage><lpage>e460</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000001402</pub-id><pub-id pub-id-type="pmid">34145166</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00165"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Formiga</surname><given-names>F.R.</given-names></name>
<name><surname>Leblanc</surname><given-names>R.</given-names></name>
<name><surname>de Souza Rebou&#x000e7;as</surname><given-names>J.</given-names></name>
<name><surname>Farias</surname><given-names>L.P.</given-names></name>
<name><surname>de Oliveira</surname><given-names>R.N.</given-names></name>
<name><surname>Pena</surname><given-names>L.</given-names></name>
</person-group><article-title>Ivermectin: An Award-Winning Drug with Expected Antiviral Activity Against COVID-19</article-title><source>J. Control. Release</source><year>2021</year><volume>329</volume><fpage>758</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.009</pub-id><pub-id pub-id-type="pmid">33038449</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00165"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Souza</surname><given-names>Z.C.</given-names></name>
<name><surname>J&#x000fa;nior</surname><given-names>F.H.X.</given-names></name>
<name><surname>Pinheiro</surname><given-names>I.O.</given-names></name>
<name><surname>de Souza Rebou&#x000e7;as</surname><given-names>J.</given-names></name>
<name><surname>de Abreu</surname><given-names>B.O.</given-names></name>
<name><surname>Mesquita</surname><given-names>P.R.R.</given-names></name>
<name><surname>de Medeiros Rodrigues</surname><given-names>F.</given-names></name>
<name><surname>Quadros</surname><given-names>H.C.</given-names></name>
<name><surname>Mendes</surname><given-names>T.M.F.</given-names></name>
<name><surname>Nguewa</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Ameliorating the Antiparasitic Activity of the Multifaceted Drug Ivermectin through a Polymer Nanocapsule Formulation</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>639</volume><fpage>122965</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.122965</pub-id><pub-id pub-id-type="pmid">37084836</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00165"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Afzal</surname><given-names>M.</given-names></name>
<name><surname>Verma</surname><given-names>M.</given-names></name>
<name><surname>Misra-Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>F.J.</given-names></name>
<name><surname>Dinda</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Improved Antifilarial Activity of Ivermectin in Chitosan&#x02014;Alginate Nanoparticles against Human Lymphatic Filarial Parasite, Brugia Malayi</article-title><source>Parasitol. Res.</source><year>2013</year><volume>112</volume><fpage>2933</fpage><lpage>2943</lpage><pub-id pub-id-type="doi">10.1007/s00436-013-3466-4</pub-id><pub-id pub-id-type="pmid">23828187</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00165"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmadpour</surname><given-names>E.</given-names></name>
<name><surname>Godrati-Azar</surname><given-names>Z.</given-names></name>
<name><surname>Spotin</surname><given-names>A.</given-names></name>
<name><surname>Norouzi</surname><given-names>R.</given-names></name>
<name><surname>Hamishehkar</surname><given-names>H.</given-names></name>
<name><surname>Nami</surname><given-names>S.</given-names></name>
<name><surname>Heydarian</surname><given-names>P.</given-names></name>
<name><surname>Rajabi</surname><given-names>S.</given-names></name>
<name><surname>Mohammadi</surname><given-names>M.</given-names></name>
<name><surname>Perez-Cordon</surname><given-names>G.</given-names></name>
</person-group><article-title>Nanostructured Lipid Carriers of Ivermectin as a Novel Drug Delivery System in Hydatidosis</article-title><source>Parasit. Vectors</source><year>2019</year><volume>12</volume><fpage>469</fpage><pub-id pub-id-type="doi">10.1186/s13071-019-3719-x</pub-id><pub-id pub-id-type="pmid">31601244</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00165"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>B.Z.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>B.B.</given-names></name>
<name><surname>Ashfaq</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>X.D.</given-names></name>
</person-group><article-title>Self-Implanted Tiny Needles as Alternative to Traditional Parenteral Administrations for Controlled Transdermal Drug Delivery</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>556</volume><fpage>338</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.12.019</pub-id><pub-id pub-id-type="pmid">30553955</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00165"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bailly</surname><given-names>C.</given-names></name>
<name><surname>Vergoten</surname><given-names>G.</given-names></name>
</person-group><article-title>Glycyrrhizin: An Alternative Drug for the Treatment of COVID-19 Infection and the Associated Respiratory Syndrome?</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>214</volume><fpage>107618</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107618</pub-id><pub-id pub-id-type="pmid">32592716</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00165"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gomaa</surname><given-names>A.A.</given-names></name>
<name><surname>Abdel-Wadood</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>The Potential of Glycyrrhizin and Licorice Extract in Combating COVID-19 and Associated Conditions</article-title><source>Phytomed. Plus</source><year>2021</year><volume>1</volume><fpage>100043</fpage><pub-id pub-id-type="doi">10.1016/j.phyplu.2021.100043</pub-id><pub-id pub-id-type="pmid">35399823</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00165"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Selyutina</surname><given-names>O.Y.</given-names></name>
<name><surname>Polyakov</surname><given-names>N.E.</given-names></name>
</person-group><article-title>Glycyrrhizic Acid as a Multifunctional Drug Carrier&#x02014;From Physicochemical Properties to Biomedical Applications: A Modern Insight on the Ancient Drug</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>559</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.01.047</pub-id><pub-id pub-id-type="pmid">30690130</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00165"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asl</surname><given-names>M.N.</given-names></name>
<name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name>
</person-group><article-title>Review of Pharmacological Effects of <italic toggle="yes">Glycyrrhiza</italic> sp. and Its Bioactive Compounds</article-title><source>Phyther. Res.</source><year>2008</year><volume>22</volume><fpage>709</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1002/ptr.2362</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-00165"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gangishetty</surname><given-names>H.</given-names></name>
<name><surname>Eedara</surname><given-names>B.B.</given-names></name>
<name><surname>Bandari</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of Ketoprofen Loaded Proliposomal Powders for Improved Gastric Absorption and Gastric Tolerance: In Vitro and In Situ Evaluation</article-title><source>Pharm. Dev. Technol.</source><year>2015</year><volume>20</volume><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.3109/10837450.2014.908306</pub-id><pub-id pub-id-type="pmid">24820852</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00165"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vanic</surname><given-names>Z.</given-names></name>
<name><surname>Planin&#x00161;ek</surname><given-names>O.</given-names></name>
<name><surname>&#x00160;kalko-Basnet</surname><given-names>N.</given-names></name>
<name><surname>Tho</surname><given-names>I.</given-names></name>
</person-group><article-title>Tablets of Pre-Liposomes Govern in Situ Formation of Liposomes: Concept and Potential of the Novel Drug Delivery System</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2014</year><volume>88</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.06.003</pub-id><pub-id pub-id-type="pmid">24929211</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00165"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abed</surname><given-names>O.S.A.</given-names></name>
<name><surname>Mulkala</surname><given-names>S.</given-names></name>
<name><surname>Sharif</surname><given-names>I.</given-names></name>
<name><surname>Abdin</surname><given-names>A.M.</given-names></name>
<name><surname>Elkordy</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Lyophilization-Free Proliposomes for Sustained Release Oral Delivery of Hydrophobic Drug (Cinnarazine): A Comparative Study</article-title><source>Pharm. Technol. Hosp. Pharm.</source><year>2021</year><volume>6</volume><fpage>20210002</fpage><pub-id pub-id-type="doi">10.1515/pthp-2021-0002</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00165"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omer</surname><given-names>H.K.</given-names></name>
<name><surname>Hussein</surname><given-names>N.R.</given-names></name>
<name><surname>Ferraz</surname><given-names>A.</given-names></name>
<name><surname>Najlah</surname><given-names>M.</given-names></name>
<name><surname>Ahmed</surname><given-names>W.</given-names></name>
<name><surname>Taylor</surname><given-names>K.M.G.</given-names></name>
<name><surname>Elhissi</surname><given-names>A.M.A.</given-names></name>
</person-group><article-title>Spray-Dried Proliposome Microparticles for High-Performance Aerosol Delivery Using a Monodose Powder Inhaler</article-title><source>AAPS PharmSciTech</source><year>2018</year><volume>19</volume><fpage>2434</fpage><lpage>2448</lpage><pub-id pub-id-type="doi">10.1208/s12249-018-1058-4</pub-id><pub-id pub-id-type="pmid">29872976</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00165"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Kushwaha</surname><given-names>P.</given-names></name>
<name><surname>Ahmad</surname><given-names>U.</given-names></name>
<name><surname>Abdullah</surname><given-names>M.</given-names></name>
</person-group><article-title>Proliposomes: An Approach for the Development of Stable Liposome</article-title><source>Ars. Pharm.</source><year>2019</year><volume>60</volume><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.30827/ars.v60i4.8517</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-00165"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muneer</surname><given-names>S.</given-names></name>
<name><surname>Masood</surname><given-names>Z.</given-names></name>
<name><surname>Butt</surname><given-names>S.</given-names></name>
<name><surname>Anjum</surname><given-names>S.</given-names></name>
<name><surname>Zainab</surname><given-names>H.</given-names></name>
<name><surname>Anwar</surname><given-names>N.</given-names></name>
<name><surname>Ahmad</surname><given-names>N.</given-names></name>
</person-group><article-title>Proliposomes as Pharmaceutical Drug Delivery System: A Brief Review</article-title><source>J. Nanomed. Nanotechnol.</source><year>2017</year><volume>8</volume><fpage>448</fpage><pub-id pub-id-type="doi">10.4172/2157-7439.1000448</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00165"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Yousaf</surname><given-names>S.</given-names></name>
<name><surname>Subramanian</surname><given-names>S.</given-names></name>
<name><surname>Korale</surname><given-names>O.</given-names></name>
<name><surname>Alhnan</surname><given-names>M.A.</given-names></name>
<name><surname>Ahmed</surname><given-names>W.</given-names></name>
<name><surname>Taylor</surname><given-names>K.M.G.</given-names></name>
<name><surname>Elhissi</surname><given-names>A.</given-names></name>
</person-group><article-title>Proliposome Powders Prepared Using a Slurry Method for the Generation of Beclometasone Dipropionate Liposomes</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>496</volume><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.10.002</pub-id><pub-id pub-id-type="pmid">26456265</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00165"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Lau</surname><given-names>K.</given-names></name>
<name><surname>Bnyan</surname><given-names>R.</given-names></name>
<name><surname>Houacine</surname><given-names>C.</given-names></name>
<name><surname>Roberts</surname><given-names>M.</given-names></name>
<name><surname>Isreb</surname><given-names>A.</given-names></name>
<name><surname>Elhissi</surname><given-names>A.</given-names></name>
<name><surname>Yousaf</surname><given-names>S.</given-names></name>
</person-group><article-title>A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization</article-title><source>Pharm. Res.</source><year>2020</year><volume>37</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1007/s11095-020-02840-w</pub-id><pub-id pub-id-type="pmid">32488363</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00165"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Byeon</surname><given-names>J.C.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Ahn</surname><given-names>J.B.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Choi</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Design of Novel Proliposome Formulation for Antioxidant Peptide, Glutathione with Enhanced Oral Bioavailability and Stability</article-title><source>Drug Deliv.</source><year>2019</year><volume>26</volume><fpage>216</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1080/10717544.2018.1551441</pub-id><pub-id pub-id-type="pmid">30843439</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00165"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karn</surname><given-names>P.R.</given-names></name>
<name><surname>Jin</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>B.J.</given-names></name>
<name><surname>Sun</surname><given-names>B.K.</given-names></name>
<name><surname>Kim</surname><given-names>M.</given-names></name>
<name><surname>Sung</surname><given-names>J.</given-names></name>
<name><surname>Hwang</surname><given-names>S.-J.</given-names></name>
</person-group><article-title>Preparation and Evaluation of Cyclosporin A-Containing Proliposomes: A Comparison of the Supercritical Antisolvent Process with the Conventional Film Method</article-title><source>Int. J. Nanomed.</source><year>2014</year><volume>9</volume><fpage>5079</fpage><lpage>5091</lpage><pub-id pub-id-type="doi">10.2147/IJN.S70340</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-00165"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheshala</surname><given-names>R.</given-names></name>
<name><surname>Hong</surname><given-names>G.C.</given-names></name>
<name><surname>Yee</surname><given-names>W.P.</given-names></name>
<name><surname>Meka</surname><given-names>V.S.</given-names></name>
<name><surname>Thakur</surname><given-names>R.R.S.</given-names></name>
</person-group><article-title>In Situ Forming Phase-Inversion Implants for Sustained Ocular Delivery of Triamcinolone Acetonide</article-title><source>Drug Deliv. Transl. Res.</source><year>2019</year><volume>9</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1007/s13346-018-0491-y</pub-id><pub-id pub-id-type="pmid">29484530</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00165"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdel-Salam</surname><given-names>F.S.</given-names></name>
<name><surname>Elkheshen</surname><given-names>S.A.</given-names></name>
<name><surname>Mahmoud</surname><given-names>A.A.</given-names></name>
<name><surname>Basalious</surname><given-names>E.B.</given-names></name>
<name><surname>Amer</surname><given-names>M.S.</given-names></name>
<name><surname>Mostafa</surname><given-names>A.A.</given-names></name>
<name><surname>Elkasabgy</surname><given-names>N.A.</given-names></name>
</person-group><article-title>In-Situ Forming Chitosan Implant-Loaded with Raloxifene Hydrochloride and Bioactive Glass Nanoparticles for Treatment of Bone Injuries: Formulation and Biological Evaluation in Animal Model</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>580</volume><fpage>119213</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119213</pub-id><pub-id pub-id-type="pmid">32165229</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00165"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nekkanti</surname><given-names>V.</given-names></name>
<name><surname>Rueda</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Betageri</surname><given-names>G.V.</given-names></name>
</person-group><article-title>Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes</article-title><source>AAPS PharmSciTech</source><year>2016</year><volume>17</volume><fpage>1019</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0428-4</pub-id><pub-id pub-id-type="pmid">26729532</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00165"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghoke</surname><given-names>S.S.</given-names></name>
<name><surname>Sood</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Pateriya</surname><given-names>A.K.</given-names></name>
<name><surname>Bhatia</surname><given-names>S.</given-names></name>
<name><surname>Mishra</surname><given-names>A.</given-names></name>
<name><surname>Dixit</surname><given-names>R.</given-names></name>
<name><surname>Singh</surname><given-names>V.K.</given-names></name>
<name><surname>Desai</surname><given-names>D.N.</given-names></name>
<name><surname>Kulkarni</surname><given-names>D.D.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Antiviral Activity of <italic toggle="yes">Ocimum sanctum</italic> and <italic toggle="yes">Acacia arabica</italic> Leaves Extracts Against H9N2 Virus Using Embryonated Chicken Egg Model</article-title><source>BMC Complement. Altern. Med.</source><year>2018</year><volume>18</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-018-2238-1</pub-id><pub-id pub-id-type="pmid">29866088</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00165"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azeem</surname><given-names>S.</given-names></name>
<name><surname>Ashraf</surname><given-names>M.</given-names></name>
<name><surname>Rasheed</surname><given-names>M.A.</given-names></name>
<name><surname>Anjum</surname><given-names>A.A.</given-names></name>
<name><surname>Hameed</surname><given-names>R.</given-names></name>
</person-group><article-title>Evaluation of Cytotoxicity and Antiviral Activity of Ivermectin Against Newcastle Disease Virus</article-title><source>Pak. J. Pharm. Sci.</source><year>2015</year><volume>28</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">25730813</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00165"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Callison</surname><given-names>S.A.</given-names></name>
<name><surname>Hilt</surname><given-names>D.A.</given-names></name>
<name><surname>Boynton</surname><given-names>T.O.</given-names></name>
<name><surname>Sample</surname><given-names>B.F.</given-names></name>
<name><surname>Robison</surname><given-names>R.</given-names></name>
<name><surname>Swayne</surname><given-names>D.E.</given-names></name>
<name><surname>Jackwood</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Development and Evaluation of a Real-Time Taqman RT-PCR Assay for the Detection of Infectious Bronchitis Virus from Infected Chickens</article-title><source>J. Virol. Methods</source><year>2006</year><volume>138</volume><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2006.07.018</pub-id><pub-id pub-id-type="pmid">16934878</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00165"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hani</surname><given-names>U.</given-names></name>
<name><surname>Osmani</surname><given-names>R.A.M.</given-names></name>
<name><surname>Alqahtani</surname><given-names>A.</given-names></name>
<name><surname>Ghazwani</surname><given-names>M.</given-names></name>
<name><surname>Rahamathulla</surname><given-names>M.</given-names></name>
<name><surname>Almordy</surname><given-names>S.A.</given-names></name>
<name><surname>Alsaleh</surname><given-names>H.A.</given-names></name>
</person-group><article-title>2<sup>3</sup> Full Factorial Design for Formulation and Evaluation of Floating Oral In Situ Gelling System of Piroxicam</article-title><source>J. Pharm. Innov.</source><year>2021</year><volume>16</volume><fpage>528</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/s12247-020-09471-z</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-00165"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alyami</surname><given-names>M.H.</given-names></name>
<name><surname>Alyami</surname><given-names>H.S.</given-names></name>
<name><surname>Abdo</surname><given-names>A.M.</given-names></name>
<name><surname>Sabry</surname><given-names>S.A.</given-names></name>
<name><surname>El-Nahas</surname><given-names>H.M.</given-names></name>
<name><surname>Ayoub</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Maximizing the Use of Ivermectin Transethosomal Cream in the Treatment of Scabies</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1026</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16081026</pub-id><pub-id pub-id-type="pmid">39204371</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00165"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albash</surname><given-names>R.</given-names></name>
<name><surname>Abdelbary</surname><given-names>A.A.</given-names></name>
<name><surname>Refai</surname><given-names>H.</given-names></name>
<name><surname>El-Nabarawi</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Use of Transethosomes for Enhancing the Transdermal Delivery of Olmesartan Medoxomil: In Vitro, Ex Vivo, and In Vivo Evaluation</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>1953</fpage><lpage>1968</lpage><pub-id pub-id-type="doi">10.2147/IJN.S196771</pub-id><pub-id pub-id-type="pmid">30936696</pub-id>
</element-citation></ref><ref id="B44-pharmaceutics-17-00165"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marques</surname><given-names>S.M.</given-names></name>
<name><surname>Shirodkar</surname><given-names>R.K.</given-names></name>
<name><surname>Kumar</surname><given-names>L.</given-names></name>
</person-group><article-title>Analytical &#x02018;Quality-by-Design&#x02019; Paradigm in Development of a RP-HPLC Method for the Estimation of Cilnidipine in Nanoformulations: Forced Degradation Studies and Mathematical Modelling of In-Vitro Release Studies</article-title><source>Microchem. J.</source><year>2023</year><volume>193</volume><fpage>109124</fpage><pub-id pub-id-type="doi">10.1016/j.microc.2023.109124</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00165"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eldin</surname><given-names>N.E.</given-names></name>
<name><surname>Elnahas</surname><given-names>H.M.</given-names></name>
<name><surname>Mahdy</surname><given-names>M.A.E.</given-names></name>
<name><surname>Ishida</surname><given-names>T.</given-names></name>
</person-group><article-title>Liposomal Pemetrexed: Formulation, Characterization and in Vitro Cytotoxicity Studies for Effective Management of Malignant Pleural Mesothelioma</article-title><source>Biol. Pharm. Bull.</source><year>2015</year><volume>38</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1248/bpb.b14-00769</pub-id><pub-id pub-id-type="pmid">25757929</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00165"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hussein</surname><given-names>N.R.</given-names></name>
</person-group><article-title>Spray-Dried Liposomes: A Study of the Effect of Carbohydrate Carrier and Concentrations on Liposome Size and Drug Entrapment</article-title><source>Zanco J. Med. Sci.</source><year>2019</year><volume>23</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.15218/zjms.2019.043</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00165"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najlah</surname><given-names>M.</given-names></name>
<name><surname>Jain</surname><given-names>M.</given-names></name>
<name><surname>Wan</surname><given-names>K.W.</given-names></name>
<name><surname>Ahmed</surname><given-names>W.</given-names></name>
<name><surname>Albed Alhnan</surname><given-names>M.</given-names></name>
<name><surname>Phoenix</surname><given-names>D.A.</given-names></name>
<name><surname>Taylor</surname><given-names>K.M.G.</given-names></name>
<name><surname>Elhissi</surname><given-names>A.</given-names></name>
</person-group><article-title>Ethanol-Based Proliposome Delivery Systems of Paclitaxel for In Vitro Application Against Brain Cancer Cells</article-title><source>J. Liposome Res.</source><year>2018</year><volume>28</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1080/08982104.2016.1259628</pub-id><pub-id pub-id-type="pmid">27834116</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00165"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nekkanti</surname><given-names>V.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Betageri</surname><given-names>G.V.</given-names></name>
</person-group><article-title>Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System</article-title><source>AAPS PharmSciTech</source><year>2016</year><volume>17</volume><fpage>851</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0388-8</pub-id><pub-id pub-id-type="pmid">26381913</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00165"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrara</surname><given-names>F.</given-names></name>
<name><surname>Benedusi</surname><given-names>M.</given-names></name>
<name><surname>Cervellati</surname><given-names>F.</given-names></name>
<name><surname>Sguizzato</surname><given-names>M.</given-names></name>
<name><surname>Montesi</surname><given-names>L.</given-names></name>
<name><surname>Bondi</surname><given-names>A.</given-names></name>
<name><surname>Drechsler</surname><given-names>M.</given-names></name>
<name><surname>Pula</surname><given-names>W.</given-names></name>
<name><surname>Valacchi</surname><given-names>G.</given-names></name>
<name><surname>Esposito</surname><given-names>E.</given-names></name>
</person-group><article-title>Dimethyl Fumarate-Loaded Transethosomes: A Formulative Study and Preliminary Ex Vivo and In Vivo Evaluation</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>8756</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23158756</pub-id><pub-id pub-id-type="pmid">35955900</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00165"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhury</surname><given-names>D.</given-names></name>
<name><surname>Tanner</surname><given-names>M.G.</given-names></name>
<name><surname>McAughtrie</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Mills</surname><given-names>B.</given-names></name>
<name><surname>Choudhary</surname><given-names>T.R.</given-names></name>
<name><surname>Seth</surname><given-names>S.</given-names></name>
<name><surname>Craven</surname><given-names>T.H.</given-names></name>
<name><surname>Stone</surname><given-names>J.M.</given-names></name>
<name><surname>Mati</surname><given-names>I.K.</given-names></name>
<etal/>
</person-group><article-title>Endoscopic Sensing of Alveolar PH</article-title><source>Biomed. Opt. Express</source><year>2016</year><volume>8</volume><fpage>243</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1364/BOE.8.000243</pub-id><pub-id pub-id-type="pmid">28101415</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00165"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janga</surname><given-names>K.Y.</given-names></name>
<name><surname>Jukanti</surname><given-names>R.</given-names></name>
<name><surname>Velpula</surname><given-names>A.</given-names></name>
<name><surname>Sunkavalli</surname><given-names>S.</given-names></name>
<name><surname>Bandari</surname><given-names>S.</given-names></name>
<name><surname>Kandadi</surname><given-names>P.</given-names></name>
<name><surname>Veerareddy</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Bioavailability Enhancement of Zaleplon via Proliposomes: Role of Surface Charge</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2012</year><volume>80</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2011.10.010</pub-id><pub-id pub-id-type="pmid">22041602</pub-id>
</element-citation></ref><ref id="B52-pharmaceutics-17-00165"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olejnik</surname><given-names>A.</given-names></name>
<name><surname>Kapuscinska</surname><given-names>A.</given-names></name>
<name><surname>Schroeder</surname><given-names>G.</given-names></name>
<name><surname>Nowak</surname><given-names>I.</given-names></name>
</person-group><article-title>Physico&#x02013;Chemical Characterization of Formulations Containing Endomorphin&#x02014;2 Derivatives</article-title><source>Amino Acids</source><year>2017</year><volume>49</volume><fpage>1719</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1007/s00726-017-2470-x</pub-id><pub-id pub-id-type="pmid">28752396</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00165"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Potluri</surname><given-names>P.</given-names></name>
<name><surname>Betageri</surname><given-names>G.V.</given-names></name>
</person-group><article-title>Mixed-Micellar Proliposomal Systems for Enhanced Oral Delivery of Progesterone</article-title><source>Drug Deliv.</source><year>2006</year><volume>13</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1080/10717540500395007</pub-id><pub-id pub-id-type="pmid">16556576</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00165"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rolim</surname><given-names>L.A.</given-names></name>
<name><surname>dos Santos</surname><given-names>F.C.M.</given-names></name>
<name><surname>Chaves</surname><given-names>L.L.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>M.L.C.M.</given-names></name>
<name><surname>Freitas-Neto</surname><given-names>J.L.</given-names></name>
<name><surname>da Silva do Nascimento</surname><given-names>A.L.</given-names></name>
<name><surname>Soares-Sobrinho</surname><given-names>J.L.</given-names></name>
<name><surname>de Albuquerque</surname><given-names>M.M.</given-names></name>
<name><surname>do Carmo Alves de Lima</surname><given-names>M.</given-names></name>
<name><surname>Rolim-Neto</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Preformulation Study of Ivermectin Raw Material</article-title><source>J. Therm. Anal. Calorim.</source><year>2015</year><volume>120</volume><fpage>807</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1007/s10973-014-3691-9</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-00165"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santonocito</surname><given-names>D.</given-names></name>
<name><surname>Puglia</surname><given-names>C.</given-names></name>
<name><surname>Torrisi</surname><given-names>C.</given-names></name>
<name><surname>Giuffrida</surname><given-names>A.</given-names></name>
<name><surname>Greco</surname><given-names>V.</given-names></name>
<name><surname>Castelli</surname><given-names>F.</given-names></name>
<name><surname>Sarpietro</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Calorimetric Evaluation of Glycyrrhetic Acid (Ga)- and Stearyl Glycyrrhetinate (Sg)-Loaded Solid Lipid Nanoparticle Interactions with a Model Biomembrane</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>4903</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26164903</pub-id><pub-id pub-id-type="pmid">34443491</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00165"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haghiralsadat</surname><given-names>F.</given-names></name>
<name><surname>Amoabediny</surname><given-names>G.</given-names></name>
<name><surname>Sheikhha</surname><given-names>M.H.</given-names></name>
<name><surname>Zandieh-Doulabi</surname><given-names>B.</given-names></name>
<name><surname>Naderinezhad</surname><given-names>S.</given-names></name>
<name><surname>Helder</surname><given-names>M.N.</given-names></name>
<name><surname>Forouzanfar</surname><given-names>T.</given-names></name>
</person-group><article-title>New Liposomal Doxorubicin Nanoformulation for Osteosarcoma: Drug Release Kinetic Study Based on Thermo and PH Sensitivity</article-title><source>Chem. Biol. Drug Des.</source><year>2017</year><volume>90</volume><fpage>368</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12953</pub-id><pub-id pub-id-type="pmid">28120466</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00165-f001"><label>Figure 1</label><caption><p>Three-dimensional response surface plots presenting the influence of the independent factors on (<bold>a</bold>) PY%, (<bold>b</bold>) EE%, (<bold>c</bold>) PS, (<bold>d</bold>) PDI, (<bold>e</bold>) ZP, and (<bold>f</bold>) Q6h.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f002"><label>Figure 2</label><caption><p>Influence of the independent factors on Y<sub>1</sub> response (PY%). (<bold>a</bold>) Effect of A at medium level of B and C. (<bold>b</bold>) Effect of B at medium level of A and C. (<bold>c</bold>) Effect of C at medium level of A and B.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f003"><label>Figure 3</label><caption><p>Influence of the independent factors on Y<sub>2</sub> response (EE%). (<bold>a</bold>) Effect of A at medium level of B and C. (<bold>b</bold>) Effect of B at medium level of A and C. (<bold>c</bold>) Effect of C at medium level of A and B.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f004"><label>Figure 4</label><caption><p>Influence of the independent factors on Y<sub>3</sub> response (PS). (<bold>a</bold>) Effect of A at medium level of B and C. (<bold>b</bold>) Effect of B at medium level of A and C. (<bold>c</bold>) Effect of C at medium level of A and B.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g004" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f005"><label>Figure 5</label><caption><p>Influence of the independent factors on Y<sub>5</sub> response (ZP). (<bold>a</bold>) Effect of A at medium level of B and C. (<bold>b</bold>) Effect of B at medium level of A and C. (<bold>c</bold>) Effect of C at medium level of A and B.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g005" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f006"><label>Figure 6</label><caption><p>Scanning electron micrographs (<bold>a</bold>) mannitol, (<bold>b</bold>) PL2, (<bold>c</bold>) PL6 at 5000&#x000d7;, and (<bold>d</bold>) photomicrograph of liposomal dispersion which formed upon hydration of DPPC based PLs.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g006" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f007"><label>Figure 7</label><caption><p>(<bold>a</bold>,<bold>b</bold>) DSC thermograms of pure IVM, SG, cholesterol, SPC, mannitol, selected formulations (PL2 and PL6), and the blank formulation.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g007" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f008"><label>Figure 8</label><caption><p>FTIR spectra of pure IVM, SG, SPC, cholesterol, mannitol, the selected formulations (PL2 and PL6), and the blank formulation.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g008" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f009"><label>Figure 9</label><caption><p>Outline of stability studies for selected formulations for 1, 2, and 3 months at 4 &#x000b1; 1 &#x000b0;C and 25 &#x000b1; 1 &#x000b0;C in terms of (<bold>a</bold>) EE% of PL2, (<bold>b</bold>) EE% of PL6, (<bold>c</bold>) PS of PL2, (<bold>d</bold>) PS of PL6, (<bold>e</bold>) ZP of PL2, and (<bold>f</bold>) ZP of PL6. * Significant (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmaceutics-17-00165-g009" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f010"><label>Figure 10</label><caption><p>Macroscopic lesions of embryos in negative control and drug-inoculated groups. (<bold>a</bold>) Negative control embryo showing normal appearance of liver. (<bold>b</bold>) Embryo inoculated with 100 &#x000b5;M of PL6 showing pale liver with hemorrhagic area. (<bold>c</bold>) Embryo inoculated with 400 &#x000b5;M of PL2 showing severely congested liver. (<bold>d</bold>) Embryo inoculated with 400 &#x000b5;M of pure IVM showing congested liver.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g010" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f011"><label>Figure 11</label><caption><p>Influence of pure IVM, PL2, and PL6 in the percentage of mortality of IBV-infected ECEs. The positive control group included 10<sup>3</sup> EID50 per 100 &#x000b5;L of IB MA5 virus. Data are the result of two independent experiments performed in duplicate. Statistical significance was assessed by two-way analysis of variance (ANOVA) with Tukey post hoc test. Values are expressed as mean &#x000b1; standard error of mean. * <italic toggle="yes">p</italic> &#x0003c; 0.05 in comparison to negative control group; # <italic toggle="yes">p</italic> &#x0003c; 0.05 in comparison to positive control group.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g011" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f012"><label>Figure 12</label><caption><p>(<bold>A</bold>) Macroscopic visualization of embryos in negative control, IBV-infected and virus-treated inoculated ECEs. [(<bold>a</bold>) Uninoculated control embryo. (<bold>b</bold>) IBV-infected embryo treated with 200 &#x000b5;M of PL2. (<bold>c</bold>) Curling and dwarfing in embryo inoculated with IBV only]. (<bold>B</bold>) The lengths of embryos in negative control, IBV-infected and virus-treated inoculated ECEs. The positive control group included 10<sup>3</sup> EID50 per 100 &#x000b5;L of IB MA5 virus. Data are the result of two independent experiments performed in duplicate. Statistical significance was assessed by two-way analysis of variance (ANOVA) with Tukey post hoc test. Values are expressed as mean &#x000b1; standard error of mean. *** <italic toggle="yes">p</italic> &#x0003c; 0.001 in comparison to negative control group and ### <italic toggle="yes">p</italic> &#x0003c; 0.001 in comparison to positive control group.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g012" position="float"/></fig><fig position="float" id="pharmaceutics-17-00165-f013"><label>Figure 13</label><caption><p>Influence of 200 &#x000b5;M of pure IVM, PL2, and PL6 in the viral load of IBV-infected ECEs 72 h post inoculation. The positive control group included 10<sup>3</sup> EID50 per 100 &#x000b5;L of IB MA5 virus. Data are the result of two independent measurements. Statistical significance was assessed by one-way analysis of variance (ANOVA) with Tukey post hoc test. Values are expressed as mean &#x000b1; standard error of mean. *** <italic toggle="yes">p</italic> &#x0003c; 0.001; ** <italic toggle="yes">p</italic> &#x0003c; 0.01 in comparison to positive control group.</p></caption><graphic xlink:href="pharmaceutics-17-00165-g013" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00165-t001"><object-id pub-id-type="pii">pharmaceutics-17-00165-t001_Table 1</object-id><label>Table 1</label><caption><p>Selected independent factors, dependent responses, and the criteria set (goals) for selecting the optimized formulation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Independent Factors</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Factors Symbol</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Unit</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Factors Type</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Factors Levels </th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low (&#x02212;1)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (+1)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carrier/lipid phase (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">Numeric</td><td align="center" valign="middle" rowspan="1" colspan="1">6:1</td><td align="center" valign="middle" rowspan="1" colspan="1">9:1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amount of SG</td><td align="center" valign="middle" rowspan="1" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">mg</td><td align="center" valign="middle" rowspan="1" colspan="1">Numeric</td><td align="center" valign="middle" rowspan="1" colspan="1">Zero</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phospholipid type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Categoric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPC</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Dependent Responses</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Response Symbol</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Unit</bold>
</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>(Goals)</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Product yield</td><td align="center" valign="middle" rowspan="1" colspan="1">Y<sub>1</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">%</td><td colspan="3" align="center" valign="middle" rowspan="1">Maximize</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Entrapment efficiency</td><td align="center" valign="middle" rowspan="1" colspan="1">Y<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">%</td><td colspan="3" align="center" valign="middle" rowspan="1">Maximize</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Particle size</td><td align="center" valign="middle" rowspan="1" colspan="1">Y<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">nm</td><td colspan="3" align="center" valign="middle" rowspan="1">Minimize</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polydispersity index</td><td align="center" valign="middle" rowspan="1" colspan="1">Y<sub>4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td colspan="3" align="center" valign="middle" rowspan="1">Minimize</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zeta potential</td><td align="center" valign="middle" rowspan="1" colspan="1">Y<sub>5</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">mV</td><td colspan="3" align="center" valign="middle" rowspan="1">Maximize (as absolute value)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cumulative percentage of drug release after 6 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>6</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Maximize</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: SG&#x02014;stearyl glycyrrhetinate; SPC&#x02014;soybean phosphatidylcholine; DPPC&#x02014;dipalmitoyl phosphatidylcholine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00165-t002"><object-id pub-id-type="pii">pharmaceutics-17-00165-t002_Table 2</object-id><label>Table 2</label><caption><p>Eight experimental runs, as suggested by 2<sup>3</sup> factorial design, and observed values of the measured responses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">A</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">B</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PY%<break/>(Y<sub>1</sub>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">EE%<break/>(Y<sub>2</sub>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PS (nm)<break/>(Y<sub>3</sub>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PDI<break/>(Y<sub>4</sub>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ZP (mV)<break/>(Y<sub>5</sub>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Q6h<break/>(Y<sub>6</sub>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL1</td><td align="center" valign="middle" rowspan="1" colspan="1">9:1</td><td align="center" valign="middle" rowspan="1" colspan="1">Zero</td><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">92.7 &#x000b1; 2.83</td><td align="center" valign="middle" rowspan="1" colspan="1">71.8 &#x000b1; 2.01</td><td align="center" valign="middle" rowspan="1" colspan="1">330.1 &#x000b1; 55.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.603 &#x000b1; 0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;42.4 &#x000b1; 4.80</td><td align="center" valign="middle" rowspan="1" colspan="1">80.95 &#x000b1; 1.36</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL2</td><td align="center" valign="middle" rowspan="1" colspan="1">6:1</td><td align="center" valign="middle" rowspan="1" colspan="1">Zero</td><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">88.6 &#x000b1; 2.19</td><td align="center" valign="middle" rowspan="1" colspan="1">83.4 &#x000b1; 0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">385.7 &#x000b1; 49.18</td><td align="center" valign="middle" rowspan="1" colspan="1">0.585 &#x000b1; 0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;50.1 &#x000b1; 1.80</td><td align="center" valign="middle" rowspan="1" colspan="1">86.59 &#x000b1; 3.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL3</td><td align="center" valign="middle" rowspan="1" colspan="1">9:1</td><td align="center" valign="middle" rowspan="1" colspan="1">Zero</td><td align="center" valign="middle" rowspan="1" colspan="1">DPPC</td><td align="center" valign="middle" rowspan="1" colspan="1">91.7 &#x000b1; 1.93</td><td align="center" valign="middle" rowspan="1" colspan="1">81.2 &#x000b1; 2.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1358.3 &#x000b1; 95.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.447 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;25.4 &#x000b1; 1.35</td><td align="center" valign="middle" rowspan="1" colspan="1">84.23 &#x000b1; 4.56</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL4</td><td align="center" valign="middle" rowspan="1" colspan="1">6:1</td><td align="center" valign="middle" rowspan="1" colspan="1">Zero</td><td align="center" valign="middle" rowspan="1" colspan="1">DPPC</td><td align="center" valign="middle" rowspan="1" colspan="1">90.2 &#x000b1; 2.61</td><td align="center" valign="middle" rowspan="1" colspan="1">88.9 &#x000b1; 0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">1462.3 &#x000b1; 28.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.327 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;18.2 &#x000b1; 0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">82.49 &#x000b1; 1.69</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL5</td><td align="center" valign="middle" rowspan="1" colspan="1">9:1</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">98.5 &#x000b1; 1.74</td><td align="center" valign="middle" rowspan="1" colspan="1">81.7 &#x000b1; 1.32</td><td align="center" valign="middle" rowspan="1" colspan="1">490.3 &#x000b1; 21.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.396 &#x000b1; 0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;40.1 &#x000b1; 1.04</td><td align="center" valign="middle" rowspan="1" colspan="1">84.59 &#x000b1; 4.19</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL6</td><td align="center" valign="middle" rowspan="1" colspan="1">6:1</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">SPC</td><td align="center" valign="middle" rowspan="1" colspan="1">97.3 &#x000b1; 0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">88.7 &#x000b1; 1.40</td><td align="center" valign="middle" rowspan="1" colspan="1">523.7 &#x000b1; 25.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.205 &#x000b1; 0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;42.4 &#x000b1; 1.10</td><td align="center" valign="middle" rowspan="1" colspan="1">88.79 &#x000b1; 2.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PL7</td><td align="center" valign="middle" rowspan="1" colspan="1">9:1</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">DPPC</td><td align="center" valign="middle" rowspan="1" colspan="1">98.8 &#x000b1; 0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">87.9 &#x000b1; 0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1695.3 &#x000b1; 46.76</td><td align="center" valign="middle" rowspan="1" colspan="1">0.528 &#x000b1; 0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;20.1 &#x000b1; 1.40</td><td align="center" valign="middle" rowspan="1" colspan="1">86.31 &#x000b1; 1.45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6:1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DPPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.1&#x000b1; 1.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.1 &#x000b1; 0.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1801.6 &#x000b1; 45.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.517 &#x000b1; 0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.7 &#x000b1; 0.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.02 &#x000b1; 1.88</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: A&#x02014;carrier to lipid phase ratio (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>); B&#x02014;SG amount (mg); C&#x02014;phospholipid type. Data represented as mean &#x000b1; SD (n = 3). PY%&#x02014;product yield percentage; EE%&#x02014;entrapment efficiency percentage; PS&#x02014;particle size; PDI&#x02014;polydispersity index; ZP&#x02014;zeta potential; Q6h&#x02014;cumulative percentage of drug released after 6 h.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00165-t003"><object-id pub-id-type="pii">pharmaceutics-17-00165-t003_Table 3</object-id><label>Table 3</label><caption><p>ANOVA statistical analysis of responses (Y<sub>1</sub>&#x02013;Y<sub>6</sub>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Suggested Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>1</sub> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>2</sub> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>3</sub> (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>4</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>5</sub> (mV)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>6</sub> (%)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linear</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linear</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linear</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-FI</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linear</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-FI</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Model</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006 *</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4922</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0056 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3698</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0216 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2073</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4408</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8404</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2647</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0013 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0081 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4638</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2842</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1928</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7780</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0014 *</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9325</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0012 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8599</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AB</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8579</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8383</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AC</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8282</td><td align="center" valign="middle" rowspan="1" colspan="1">---</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2188</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8756</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant factors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A, B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A, B, C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B, C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">----</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">----</td></tr><tr><td colspan="7" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>R<sup>2</sup> Analysis</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9762</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9821</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9929</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9237</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9451</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9589</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adequate precision</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.2385</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.5932</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.4301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2675</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.6516</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.0941</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjusted R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9584</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9688</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9875</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9039</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7124</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Predicted R<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9049</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9286</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9715</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.8833</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7803</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.6297</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Y<sub>1</sub>&#x02014;product yield (PY); Y<sub>2</sub>&#x02014;entrapment efficiency (EE); Y<sub>3</sub>&#x02014;particle size (PS); Y<sub>4</sub>&#x02014;polydispersity index (PDI); Y<sub>5</sub>&#x02014;zeta potential (ZP); Y<sub>6</sub>&#x02014;cumulative percentage of drug released after 6 h (Q6h); A&#x02014;carrier/lipid ratio (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>); B&#x02014;SG amount (mg); C&#x02014;phospholipid type. * Significant (<italic toggle="yes">p</italic> &#x0003c; 0.05).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00165-t004"><object-id pub-id-type="pii">pharmaceutics-17-00165-t004_Table 4</object-id><label>Table 4</label><caption><p>In vitro release kinetics data of the prepared PLs formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Release Model</th><th colspan="8" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">R<sup>2</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL3</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL4</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL5</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL6</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL7</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PL8</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zero order</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1912</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2646</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2565</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1951</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0545</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0737</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0860</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0536</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">First order</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8923</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9381</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9070</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9019</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9403</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9303</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9257</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Higuchi</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8727</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9009</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8547</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8131</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8174</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8122</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8021</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9612</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9722</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9762</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9363</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9387</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9365</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9236</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9246</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hixson&#x02013;Crowell</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7961</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8662</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8153</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8312</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8286</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8886</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8784</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8710</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Best fit model</td><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" rowspan="1" colspan="1">First order</td><td align="center" valign="middle" rowspan="1" colspan="1">First order</td><td align="center" valign="middle" rowspan="1" colspan="1">First order</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n-value of Korsmeyer&#x02013;Peppas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.312</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.328</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.324</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.318</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.283</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.287</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.293</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.284</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00165-t005"><object-id pub-id-type="pii">pharmaceutics-17-00165-t005_Table 5</object-id><label>Table 5</label><caption><p>Predicted and observed values for the optimized formulation (PL6).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>1</sub> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>2</sub> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>3</sub> (nm)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>4</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>5</sub> (mV)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Y<sub>6</sub> (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Predicted values</td><td align="center" valign="middle" rowspan="1" colspan="1">96.775</td><td align="center" valign="middle" rowspan="1" colspan="1">89.35</td><td align="center" valign="middle" rowspan="1" colspan="1">591.675</td><td align="center" valign="middle" rowspan="1" colspan="1">0.240</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;42.325</td><td align="center" valign="middle" rowspan="1" colspan="1">89.276</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observed values</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">523.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;42.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88.79</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Y<sub>1</sub>&#x02014;product yield (PY); Y<sub>2</sub>&#x02014;entrapment efficiency (EE); Y<sub>3</sub>&#x02014;particle size (PS); Y<sub>4</sub>&#x02014;polydispersity index (PDI); Y<sub>5</sub>&#x02014;zeta potential (ZP); Y<sub>6</sub>&#x02014;cumulative percentage of drug released after 6 h (Q6h).</p></fn></table-wrap-foot></table-wrap></floats-group></article>